

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: a protocol paper

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032636
Article Type:	Protocol
Date Submitted by the Author:	01-Jul-2019
Complete List of Authors:	Rapport, Frances ; Macquarie University, Australian Institute of Health Innovation Smith, Andrea; Macquarie University, Australian Institute of Health Innovation Cust, Anne; The University of Sydney, Sydney Medical School Mann, Graham; University of Sydney, Western Clinical School, Westmead Millenium Institute Watts, Caroline; University of Sydney, Sydney School of Public Health Gyorki, David; Peter MacCallum Cancer Centre Henderson, Michael; Peter MacCallum Cancer Institute, Cancer Surgery Hong, Angela; Melanoma Institute Australia Kelly, John; Alfred Health, Victorian Melanoma Service Long, Georgina; Melanoma Institute Australia Mar, Victoria; Alfred Health, Victorian Melanoma Service Morton, Rachael; NHMRC Clinical Trials Centre Saw, Robyn; Melanoma Institute Australia Scolyer, Richard; University of Sydney, Sydney Medical School Spillane, Andrew; Melanoma Institute Australia Thompson, John ; Melanoma Institute Australia Braithwaite, Jeffrey; Macquarie University, Australian Institute of Health Innovation
Keywords:	QUALITATIVE RESEARCH, melanoma, sentinel lymph node biopsy, implementation science, systemic adjuvant therapy, Dermatological tumours < ONCOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**TITLE**

Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: a protocol paper

**Authors:** Frances Rapport,\*<sup>1</sup> Andrea L Smith,\*<sup>1</sup> Anne E Cust,<sup>2,3</sup> Graham Mann,<sup>3,4</sup> Caroline Watts,<sup>2,5</sup> David Gyorki,<sup>6</sup> Michael Henderson,<sup>6</sup> Angela Hong,<sup>3,7</sup> John Kelly,<sup>8</sup> Georgina Long,<sup>3,7</sup> Victoria Mar,<sup>8</sup> Rachael Morton,<sup>3,9</sup> Robyn Saw,<sup>3,7</sup> Richard Scolyer,<sup>3,7</sup> Andrew Spillane,<sup>3,7</sup> John Thompson,<sup>3</sup> Jeffrey Braithwaite<sup>1</sup>

\* These authors contributed equally to this work.

<sup>1</sup> Faculty of Medicine and Health Sciences, Australian Institute of Health Innovation, Macquarie University, Sydney, Australia

<sup>2</sup> Cancer Epidemiology and Prevention Research, Sydney School of Public Health, The University of Sydney, Australia

<sup>3</sup> Melanoma Institute Australia The University of Sydney, Sydney, Australia

<sup>4</sup> Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Westmead, Australia

<sup>5</sup> Surveillance, Epidemiology and Prevention Program, Kirby Institute, UNSW, Sydney, Australia

<sup>6</sup> Peter MacCallum Cancer Centre, Melbourne, Australia

<sup>7</sup> Sydney School of Medicine and Health, University of Sydney, Sydney, Australia

<sup>8</sup> Victorian Melanoma Service, The Alfred, Melbourne, Australia

<sup>9</sup> NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

**Correspondence to** Andrea L Smith: [andrea.smith@mq.edu.au](mailto:andrea.smith@mq.edu.au)

**Journal:** BMJ Open

**Word count** 3498 (excluding Abstract, Article Summary, tables and boxes, acknowledgements and references)

**Keywords** Mixed methods; melanoma; sentinel lymph node biopsy; implementation science; systemic adjuvant therapy; clinical practice guidelines

## 1        1    **ABSTRACT**

2        2    **Introduction:** Sentinel lymph node biopsy (SLNB) is a diagnostic procedure developed in the 1990s. It  
3        3    is currently used to stage patients with primary cutaneous melanoma, provide prognostic  
4        4    information and guide management. The Australian Clinical Practice Guidelines state that SLNB  
5        5    should be considered for patients with cutaneous melanoma >1mm in thickness (or >0.75mm with  
6        6    high-risk pathology features). Until recently, SLN status was used to identify patients who might  
7        7    benefit from a completion lymph node dissection, a procedure that is no longer routinely  
8        8    recommended. SLN status is now also being used to identify patients who might benefit from  
9        9    systemic adjuvant therapies such as anti-PD1 checkpoint inhibitor immunotherapy or BRAF-directed  
10       10    molecular targeted therapy, treatments that have significantly improved relapse-free survival for  
11       11    patients with resected stage III melanoma and improved overall survival of patients with  
12       12    unresectable stage III and stage IV melanoma. Australian and international data indicate that  
13       13    approximately half of eligible patients receive a SLNB.

14       14    **Methods and analysis:** This mixed-methods study seeks to understand the structural, contextual and  
15       15    cultural factors affecting implementation of the SLNB guidelines. Data collection will include: (1)  
16       16    cross-sectional questionnaires and semi-structured interviews with general practitioners and  
17       17    dermatologists; (2) semi-structured interviews with other healthcare professionals involved in the  
18       18    diagnosis and early definitive care of melanoma patients, and key stakeholders including  
19       19    researchers, representatives of professional colleges, training organisations, and consumer  
20       20    melanoma groups; and (3) documentary analysis of documents from government, health services  
21       21    and non-government organisations. Descriptive analyses and multivariable regression models will be  
22       22    used to examine factors related to SLNB practices and attitudes. Qualitative data will be analysed  
23       23    using thematic analysis.

24       24    **Ethics and dissemination:** Ethics approval has been granted by the University of Sydney. Results will  
25       25    be disseminated through publications and presentations to clinicians, patients, policymakers and  
26       26    researchers, and will inform the development of strategies for implementing SLNB guidelines in  
27       27    Australia.

28  
29

## ARTICLE SUMMARY

This is the first Australian study to examine the structural, contextual and cultural factors affecting implementation of national clinical practice guidelines for SLNB in patients with melanoma.

The data generated may help to inform clinical guideline implementation strategies for melanoma and other cancers in Australia and internationally.

### Strengths and limitations of this study

The mixed-method design, comprising cross-sectional questionnaires, in-depth interviews and documentary analysis, will generate rich data from a wide range of healthcare professional and stakeholder perspectives.

The purposive recruitment of healthcare professionals and stakeholders, and the sampling and selection of documents and policies, may introduce selection biases.

## INTRODUCTION

### *Centre of Research Excellence in Melanoma*

The Centre of Research Excellence (CRE) in Melanoma is an Australian collaboration of clinicians, researchers and implementation scientists from melanoma centres and universities in New South Wales (Melanoma Institute Australia; The University of Sydney; and the Australian Institute of Health Innovation, Macquarie University) and Victoria (Peter MacCallum Cancer Centre; Victorian Melanoma Service Alfred Hospital; The University of Melbourne; Monash University and the Skin and Cancer Foundation), Australia, and is funded by the National Health and Medical Research Council (NHMRC). The Melanoma CRE, like all Australian government-funded CREs, is tasked with three primary objectives: pursuing collaborative research; developing capacity; and promoting translation of research outcomes into policy and practice. This third objective is the focus of the mixed-methods study outlined in this protocol paper, in particular to understand the structural, contextual and cultural factors affecting implementation of the recently updated national clinical practice guidelines for SLNB for melanoma patients in Australia.

### *Prioritisation of SLNB uptake as a key implementation goal*

One of the rationales behind embedding implementation science expertise within the Melanoma CRE is to support the transfer of evidence-based, effective and efficient patient-centred care across and beyond the Melanoma CRE research sites so that all melanoma patients, regardless of location in Australia, can benefit from its generation of knowledge. A necessary first step in the

60 implementation process is to identify and prioritise interventions with the greatest potential to  
 61 impact positively on the quality of care for patients with melanoma. Between December 2018 and  
 62 February 2019, meetings of Melanoma CRE members systematically mapped CRE projects across the  
 63 melanoma care continuum (Supplementary file 1) and identified two in which implementation  
 64 science had the greatest potential to identify pathways to practice change. One of these, 'SLNB for  
 65 patients with melanoma', is outlined in this protocol paper.

### 66 *Melanoma diagnosis and staging*

67 Melanoma is the fourth most common cancer diagnosis in Australia.[1] In 2019, it is estimated that  
 68 15,229 people will be diagnosed with invasive melanoma and that 1,725 people will die from it.[1]  
 69 Between 2011 and 2015, an individual diagnosed with melanoma had a 91% chance of surviving for  
 70 5 years.[1] Survival is influenced by the stage of the melanoma at diagnosis. Staging takes into  
 71 account tumour thickness and ulceration and whether the melanoma has spread regionally (to the  
 72 lymph nodes) or more distantly (to other parts of the body) (Table 1).[2,3] Accurate staging is a  
 73 fundamental prerequisite for optimal melanoma management. From the perspective of the  
 74 individual patient, staging provides important prognostic information, guides management and  
 75 clinical decision-making, including whether a patient may benefit from adjuvant systemic therapy,  
 76 shapes communication between the patient, their clinician, and the patient's family and may  
 77 determine the patient's eligibility for clinical trials.[4] From a public health perspective, staging also  
 78 facilitates standardised reporting, centralised cancer registry reporting, the design and conduct of  
 79 clinical trials, and the analysis of clinical trial data.[2]

80 **Table 1. Staging categories for cutaneous melanoma [2,3]**

Stage	Definition
Stage 0	The melanoma is confined to the cells in the top layer of the skin (epidermis) and has not invaded the deeper layers (dermis); also known as <i>in situ</i> melanoma (in contrast to stages I to IV, which are referred to as invasive melanoma)
Stage I	The melanoma has not spread beyond the primary site (i.e. no metastases or lymph node involvement); the melanoma is: <ul style="list-style-type: none"> <li>• ≤ 2mm in thickness <u>without</u> ulceration</li> <li>• ≤ 1mm in thickness <u>with</u> ulceration</li> </ul>
Stage II	The melanoma has not spread beyond the primary site (i.e. no metastases or lymph node involvement); the melanoma is: <ul style="list-style-type: none"> <li>• &gt; 2mm in thickness <u>without</u> ulceration</li> <li>• &gt; 1mm in thickness <u>with</u> ulceration</li> </ul>

Stage	Definition
Stage III	The melanoma can be any thickness and locoregional metastasis is present (i.e. satellite, in-transit or micrometastases or nodal metastases)
Stage IV	The melanoma can be any thickness and has spread to distant lymph nodes and organs e.g. lungs, liver, brain or bone

81

82 *SLNB*

83 An important primary melanoma staging tool is SLNB, a multiphase procedure involving cutaneous  
 84 lymphatic mapping with lymphoscintigraphy in the nuclear medicine department, surgical removal  
 85 of the localised lymph nodes, and pathological assessment of the nodes for the presence of  
 86 metastatic disease. The procedure has a high degree of accuracy for identifying patients with  
 87 melanoma who have clinically occult metastases in their regional lymph nodes.[5,6]

88 Prior to the introduction of SLNB by Morton *et al.* in 1992,[5] the only way to detect spread  
 89 from the primary tumour site to the regional lymph nodes was through clinical examination of the  
 90 patient's lymph nodes or by performing an elective lymph node dissection with all its attendant  
 91 morbidity. Elective lymph node dissection was routinely offered to patients who were considered to  
 92 be at risk of relapse in the belief that removal of all lymph nodes in the lymph node field would  
 93 prevent distant spread of the melanoma to other parts of the body. However, as only a small  
 94 proportion (about 20%) of those at-risk patients who had an elective lymph node dissection actually  
 95 had nodal metastases, the procedure resulted in considerable unnecessary morbidity, primarily  
 96 lymphoedema.

97 SLNB avoided this unnecessary morbidity by using localising nuclear medicine and vital blue  
 98 dyes to identify the SLN, that is, the lymph node receiving direct lymphatic drainage from the  
 99 primary melanoma site.[5] The rationale (which Morton referred to as the incubator hypothesis or  
 100 step-wise model of disease progression) was that the most likely site of early metastases, the SLN,  
 101 could then be removed and tested pathologically for clinically occult melanoma cells and, if found, a  
 102 completion lymph node dissection performed. Conversely, if the SLN was clear of metastatic disease,  
 103 then it was reasoned that it was unlikely that other, more distant nodes would be diseased, thereby  
 104 saving the patient from an unnecessary lymph node dissection. In this context, SLNB has been  
 105 reported to be cost-effective for the management of intermediate thickness melanoma. [7]

106

107



### 108 *Contemporary melanoma management*

109 Based on the results of two recent randomised controlled trials,[8,9] it is now widely accepted that a  
110 completion lymph node dissection in patients who are SLN-positive does not provide a survival  
111 benefit. Consequently, the role SLNB plays in contemporary melanoma management is changing. In  
112 Australia, in addition to providing staging and prognostic information, SLNB is now being used to  
113 identify patients who might benefit from adjuvant systemic therapy. Adjuvant systemic therapies,  
114 such as immunotherapies (in which the patient's own immune system is activated to target cancer  
115 cells) and BRAF-directed targeted molecular therapies (which block the growth and spread of cancer  
116 by interfering with specific abnormal molecules within the tumour cells themselves), have been  
117 developed on the basis of recent advances in our understanding of the molecular and immune  
118 biology of melanoma. These adjuvant systemic therapies have been shown to significantly prolong  
119 survival in patients with unresectable stage III and stage IV melanoma[10] and have also been shown  
120 to improve recurrence-free survival when administered as adjuvant therapy in patients with  
121 resected stage III melanoma.[11–13] However, they are not yet publicly funded in the adjuvant  
122 melanoma setting in Australia. Consequently, access is often restricted to clinical trials, eligibility for  
123 which requires staging via SLNB, and compassionate access schemes.

### 124 *International (AJCC staging system) and national (Australian) guidelines for SLNB*

125 The American Joint Committee on Cancer (AJCC) Staging Manual has become the benchmark for  
126 classifying patients' disease stage, outlining prognosis, and establishing the best treatment  
127 approaches.[14] The recently updated eighth edition recommends that lymphatic mapping and SLNB  
128 should be routinely used as a staging procedure for patients with T1b, T2, T3 or T4 primary  
129 cutaneous melanomas (i.e. melanomas  $\geq 0.8$ mm with or without ulceration, or  $< 0.8$ mm with  
130 ulceration) and who have clinically negative regional lymph nodes.[3] Likewise, the 2018 Australian  
131 Clinical Practice Guidelines for the Diagnosis and Management of Melanoma recommend that 'SLNB  
132 should be considered for all patients with melanoma  $> 1$  mm in thickness and for patients with  
133 melanoma  $> 0.75$  mm with other high risk pathological features to provide optimal staging and  
134 prognostic information and to maximise management options for patients who are node  
135 positive.'[15]

### 136 *Rates of SLNB in Australia and internationally*

1  
2  
3 137 The limited data that exist for rates of SLNB for melanoma in Australia indicate that these rates may  
4  
5 138 be lower than expected.<sup>a</sup> A population-based study in Queensland between 2010 and 2014 reported  
6  
7 139 rates of SLNB of 33% (261 out of 787 study patients) for stage 1b and stage 2 melanoma  
8  
9 140 patients.[16] The 2006 New South Wales Melanoma Patterns of Care Study reported that SLNB was  
10  
11 141 performed in 45% of patients diagnosed with a melanoma >0.75mm thick.[17] SLNB rates in  
12  
13 142 Australia are roughly comparable to rates reported internationally. Data from the US Surveillance  
14  
15 143 Epidemiology and End Results (SEER) database for 2004-2006 indicate that 53% of eligible patients  
16  
17 144 received a SLNB,[18] while data from a population-based study in the northeast of France indicated  
18  
19 145 that 34% of patients with a melanoma >1mm in thickness received a SLNB.[19] Factors associated  
20  
21 146 with having a SLNB included patient age <50 years,[17] primary tumour on upper limb,[17]  
22  
23 147 treatment in an urban setting,[17,19–23] and hospital size (>50 beds)[24] Recent international data  
24  
25 148 indicate that rates of SLNB are increasing: in the Netherlands the SLNB rate increased from 39.0% in  
26  
27 149 2003 to 47.8% in 2014.[25] The authors suggest that changes in rates of SLNB may be related to  
28  
29 150 evolving views on SLNB as a staging or therapeutic procedure, changes to the AJCC staging system,  
30  
31 151 and less acceptance of the step-wise model of disease progression.

### 32 152 *Challenges relating to implementation of clinical practice guidelines*

33 153 Clinical practice guidelines synthesise and summarise complex research evidence into easily  
34  
35 154 understandable recommendations. Clinical practice guidelines were initially heralded as a means of  
36  
37 155 overcoming the knowledge gaps perceived to be behind observed variations in clinical practice.[26]  
38  
39 156 However, even guidelines that are based on rigorous evidence rarely penetrate medical practice as  
40  
41 157 intended.[26] It is now accepted that the distillation and summary of evidence into clinical practice  
42  
43 158 guidelines, although a necessary step, is not in and of itself sufficient for the translation of research  
44  
45 159 evidence into routine clinical practice.[26]

46  
47 160 Successful adoption and implementation of guidelines requires an understanding of the  
48  
49 161 technical, social, political, economic, cultural, structural and psychological barriers to the use of  
50  
51 162 research evidence.[27] As Greenhalgh and colleagues noted in 2004, clinicians are not passive  
52  
53 163 recipients of innovations (such as guidelines).[28] Instead they 'seek innovations, experiment with  
54  
55 164 them, evaluate them, find (or fail to find) meaning in them, develop feelings (positive or negative)  
56  
57 165 about them, challenge them, worry about them, complain about them, "work around" them, gain

---

58  
59  
60  
<sup>a</sup> Rates of SLNB are likely to be related to the guidelines in place at that point in time. In Australia the 1999 guidelines stated 'Lymphatic mapping and sentinel node biopsy should be considered for all melanomas >1mm thick provided they can be done in the context of a controlled clinical trial and by surgeons trained in these procedures'; the 2008 guidelines stated 'Patients with a melanoma >1.0mm in thickness should be given the opportunity to discuss sentinel lymph node biopsy to provide staging and prognostic information'.

1  
2  
3 166 experience with them, modify them to fit particular tasks, and try to improve or re-design them—  
4  
5 167 often through dialogue with other users.’ In addition, as Ferlie and colleagues noted in 2001, the  
6  
7 168 research evidence for a particular practice is often ambiguous and contested.[29] Consequently, the  
8  
9 169 evidence base, ‘must be continually interpreted and reframed in accordance with the local context, a  
10  
11 170 process that often involves power struggles among various professional groups’.[29] For their  
12  
13 171 widespread acceptance, guidelines need to be perceived as authoritative, credible and professional  
14  
15 172 documents that help healthcare professionals improve their practice, traits closely tied to the  
16  
173 provenance of the guidelines.[26]

17  
18 174 Consequently, if widespread guideline implementation is to be achieved in Australia, it will  
19  
20 175 be necessary to understand the complex contextual factors influencing clinicians’ attitudes and  
21  
22 176 behaviour in relation to the decision to discuss SLNB with an eligible melanoma patient or to refer  
23  
24 177 the patient to an appropriate specialist for discussion of the pros and cons of SLNB. The knowledge  
25  
26 178 generated in this project will be used to inform future efforts to support effective and widespread  
27  
28 179 melanoma guideline implementation in Australia. A greater awareness of the guidelines, and the  
29  
30 180 melanoma patients to whom they apply, should in turn lead to improved melanoma management  
31  
32 181 and outcomes for patients, including more accurate information about prognosis and access to  
33  
34 182 systemic adjuvant therapies such as immunotherapy or targeted molecular therapy for eligible  
35  
36 183 patients with melanoma.

## 184 **METHODS AND ANALYSIS**

### 185 **Study design**

186 This protocol outlines the research design for a mixed-methods study. Cross-sectional  
187 questionnaires and in-depth semi-structured interviews with GPs and dermatologists, and in-depth  
188 semi-structured interviews with other healthcare professionals and stakeholders in melanoma care  
189 in Australia will be complemented by data collected through documentary analysis of material such  
190 as editorials, organisational and institutional reports, books and brochures relating to SLNB in  
191 Australia, including policy documentation (Table 2). Data collection for GP questionnaires and  
192 interviews commenced in December 2018; and for other healthcare professionals and stakeholders  
193 in May 2019. The study runs until 2023. The credibility of the study’s findings will be enhanced  
194 through the use of multiple sources of information, different methods of data collection and the  
195 involvement of researchers with diverse areas of expertise (e.g. in clinical practice, melanoma,  
196 implementation science, complexity science, behaviour change science and public health). This  
197 triangulation of methods, data sources and investigator expertise will ensure that the findings are

198 data-rich and comprehensive.[30] The reporting of the study design as outlined in this protocol is  
 199 informed by the consolidated Criteria for Reporting Qualitative Research (COREQ) checklist and the  
 200 Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines.[31,32]

### 201 **Study aim and objectives**

202 The aim of this mixed-methods study is to understand the structural, contextual and cultural factors  
 203 impacting the implementation of the recently updated national clinical practice guidelines for SLNB  
 204 in melanoma patients. The study aim will be achieved by fulfilling the objectives outlined in Table 2.

205 **Table 2 Study aim, objectives and data collection methods**

Aim	Objectives	Data collection
To understand the structural, contextual and cultural factors impacting the implementation of the national clinical practice guidelines for SLNB for melanoma patients in Australia	Understand GPs' and dermatologists' knowledge and attitudes towards SLNB in Australia  Examine, document and analyse the discourse surrounding SLNB in Australia	Questionnaires and follow-up semi-structured interviews with GPs (i.e. generalist GPs and GPs working in skin cancer clinics) and dermatologists in relation to management of melanoma and role of SLNB
	Provide an account of factors that have contributed to this discourse	Semi-structured interviews with other healthcare professionals and key stakeholders in melanoma management (e.g. academics and researchers, representatives of professional colleges, healthcare training and education organisations, and consumer advocacy organisations)
	Assess the range of perspectives and opinions on SLNB among healthcare professionals and other stakeholders in Australia	
	Contextualise data collected in the interviews with other documentation	Documentary analysis of printed and electronic material relating to implementation of SLNB guidelines in Australia (e.g. commentaries and editorials, books and brochures, event programs, newspapers, press releases, program proposals, summaries, organisational and institutional
	Provide an account of factors that have impacted on the implementation of Australia's clinical practice guidelines for SLNB for patients with melanoma	
	Generate knowledge that will help inform the future work of the CRE in Melanoma, in	

---

particular strategies to improve reports, questionnaire data,  
uptake of the clinical practice and public records)  
guidelines for SLNB in melanoma  
patients in Australia

---

206

## 207 **Sample and setting**

### 208 *Participants*

209 Participants will include GPs, dermatologists and other healthcare professionals involved in the  
210 diagnosis and early definitive care of melanoma patients in Australia (Box 1). It is anticipated this will  
211 include generalist GPs, GPs working in skin cancer clinics, dermatologists and surgeons (general,  
212 plastic and surgical oncology). Participants will also include stakeholders involved in melanoma care  
213 in Australia, including researchers, representatives of professional colleges and organisations (e.g.  
214 Royal Australian College of General Practitioners, Royal Australasian College of Surgeons, Australian  
215 College of Dermatologists, Skin Cancer College Australasia), healthcare training and education  
216 organisations (e.g. HealthCert, Australasian College of Cutaneous Oncology), and consumer advocacy  
217 organisations (e.g. Melanoma Patients Australia).

### 218 **Box 1 Inclusion and exclusion criteria**

#### 219 Questionnaires and interviews (GPs and dermatologists)

- 220 • Must have worked as a general practitioner or dermatologist in Australia in the previous  
221 12 months.

#### 222 Interviews (other healthcare professionals)

- 223 • Must have worked as a health professional in Australia in the previous 12 months.

#### 224 Interviews (stakeholders)

- 225 • Current or prior experience of managing patients with melanoma in Australia; or
- 226 • Current or prior experience of working for an organisation or institution that could have  
227 influenced healthcare practitioners', policymakers' or patients' views on SLNB in Australia.

#### 228 Documentary analysis

- 229 • Australian online or print-based materials that could have influenced healthcare practitioners',  
230 policymakers' or patients' views on SLNB in Australia.

1  
2  
3 231 *Sampling and recruitment: interviews*  
4

5 232 Sampling will be driven by a number of purposive sampling strategies, including stratified purposive  
6  
7 233 sampling and maximum variation sampling (to gain as wide a range of perspectives as possible from  
8  
9 234 individuals with different professional backgrounds and responsibilities), key informant sampling (to  
10  
11 235 ensure important informants are included) and snowball sampling (to ensure sampling is not  
12  
13 236 restricted to key informants already known to the CRE in Melanoma members).[33] Sampling will be  
14  
15 237 iterative, with decisions informed by the ongoing data analysis.[34] Recruitment strategies will  
16  
17 238 include: (1) recruitment of healthcare professionals at relevant conferences and professional  
18  
19 239 development activities; (2) identification of key stakeholders by members of the CRE in Melanoma;  
20  
21 240 and (3) identification of additional key stakeholders by participants. The overarching recruitment  
22  
23 241 strategy will be to select for interview individuals from around Australia whose experiences and  
24  
25 242 professional roles within melanoma healthcare put them in a position to provide rich and relevant  
26  
27 243 data. Recruitment will cease once data analysis indicates thematic saturation has been reached, this  
28  
29 244 being the point at which our analysis allows us to provide a comprehensive and credible account of  
30  
31 245 the structural, contextual and cultural factors impacting on implementation of the national clinical  
32  
33 246 practice guidelines for SLNB in patients with melanoma in Australia. It is anticipated that between 50  
34  
35 247 and 65 participants will be recruited in order to ensure a variety of perspectives and experiences  
36  
37 248 from all relevant sectors in Australian melanoma care (20-25 GPs; 10-15 dermatologists; 20-25 other  
38  
39 249 healthcare professionals and stakeholders).

40  
41  
42 250 *Sampling: documentary analysis*  
43

44 251 Documentary materials relevant to the development and use of the national SLNB guidelines will be  
45  
46 252 purposively sampled and included, based on their potential to provide background and contextual  
47  
48 253 information relevant to study's aims (Box 1). Relevant documentary materials (such as  
49  
50 254 commentaries and editorials, journal articles and white papers, books and brochures, event  
51  
52 255 programs, newspapers, press releases, program proposals, summaries, organisational and  
53  
54 256 institutional reports, questionnaire data, and public records) will be used to uncover meaning,  
55  
56 257 develop understanding and discover insights relevant to the study's aim.

57  
58  
59 258 **Data collection**  
60

61 259 *Questionnaires*

62 260 Questionnaires for GPs and dermatologists have been developed following a review of literature and  
63  
64 261 consultation with melanoma clinicians and dermatologists. Data captured will include demographic  
65  
66 262 characteristics, knowledge of melanoma guidelines, clinical management of patients with

263 melanoma, referral patterns, attitudes to SLNB, and experiences of sharing care of patients with  
 264 melanoma with other healthcare providers (Supplementary file 2). The questionnaires can be  
 265 completed on paper or electronically. The questionnaire data will be managed using REDCap.[35]

### 266 *Interviews*

267 Semi-structured interview guides have been developed for healthcare professionals and  
 268 stakeholders based on a review of literature and through consultation with melanoma healthcare  
 269 professionals (Table 3). The interview guides outline the major topics that will be discussed in the  
 270 interviews and include a range of questions and prompts. Interviews will be face-to-face or by  
 271 telephone (depending on participant preference) and will be audio-recorded and professionally  
 272 transcribed. Field notes written up immediately after each interview will further inform and enrich  
 273 data analysis.

274 **Table 3 Topics and example questions from semi-structured interview guides for melanoma**  
 275 **healthcare professionals (GPs and dermatologists) and stakeholders**

Topics	Example questions
<i>Melanoma healthcare professionals</i>	
Risk factors, diagnosis and management	If you identified a suspected melanoma, how would you usually go about getting a biopsy? If you perform the biopsy yourself, how does the information in the pathology report help guide your subsequent management decisions?
SLNB	Do you have any thoughts about the role of SLNB in the management of patients with melanoma? What do you see as the benefits and risks of SLNB?
Shared decision-making	How comfortable would you feel about discussing melanoma management options with a patient? How do you usually tell your patient about different options for managing their melanoma?
<i>Stakeholders in melanoma care</i>	
Professional / organisational role	Can you tell me about your involvement / your organisation's involvement in SLNB for melanoma? Can you tell me about how you / your organisation regards SLNB for melanoma?
Views on current SLNB guidelines	I know you have written about SLNB, can you expand on that? There are some who hold quite extreme views on SLNB. How do you respond to these views?
Making changes in relation to SLNB	What might be the barriers to change? What do you think will happen in relation to use of SLNB in the next 5 years / 10 years?

276 SLNB: sentinel lymph node biopsy.

277



1  
2  
3 278 *Documentary analysis*  
4

5 279 Documents will initially be identified through discussion with members of the Melanoma CRE, and  
6  
7 280 then through targeted, systematic searches of electronic and print-based resources relating to SLNB  
8  
9 281 and SLNB guidelines in Australia. Searching will be iterative and cease only when a comprehensive  
10  
11 282 understanding of the background and context of SLNB in Australia has been reached.

12  
13 283 **Data analysis**

14  
15 284 *Questionnaires*

16  
17 285 Postcode will be classified using the Accessibility/Remoteness Index of Australia (ARIA), and Socio-  
18  
19 286 Economic Indexes for Areas (SEIFA) classifications.[36,37] Descriptive analyses and multivariable  
20  
21 287 regression models will be used to examine factors related to SLNB practices and attitudes, and  
22  
23 288 familiarity with the Australian clinical practice guidelines for melanoma management, estimated  
24  
25 289 using probability ratios and 95% confidence intervals (CIs). Potential predictors that will be assessed  
26  
27 290 in the regression models include age, sex, type of practice, years of practice, number of invasive  
28  
29 291 melanomas diagnosed in a year, location of practice and GPs' exposure to information relating to  
30  
31 292 SLNB. All analyses will be conducted using SAS version 9.4 (SAS Institute Inc).

32  
33 293 *Interviews*

34 294 Analysis of interview data will be based on Braun and Clarke's method of thematic analysis and will  
35  
36 295 initially be inductive and data driven.[38,39] In line with Braun and Clarke's methods, analysis will go  
37  
38 296 beyond the semantic content of the data to: 'identify underlying ideas, assumptions and  
39  
40 297 conceptualisations – and ideologies – that are theorised as shaping or informing the semantic  
41  
42 298 content of the data'.[39] The de-identified transcripts will be read by two members of the research  
43  
44 299 team. Data will be compared within and across interviews in order to identify commonalities,  
45  
46 300 differences and patterns in the data. Transcripts will be coded by the two researchers and a list of  
47  
48 301 themes and categories relevant to the study's aim generated. These themes will then be discussed  
49  
50 302 with other members of the research team and refined until group agreement is reached on those  
51  
52 303 most relevant to the study's aim. A thematic map will be developed and the data recoded to these  
53  
54 304 themes. Analytic memos will be written throughout the data analysis process.

55  
56 305 *Documentary materials*

57 306 The analysis process will commence by assessing the authenticity and usefulness of each document,  
58  
59 307 taking into account the document's relevance to the study's aim, the original purpose of the  
60  
308 document, the context in which it was produced, and the intended audience.[40] As with the



1  
2  
3 309 interview data, the documentary data will be analysed using Braun and Clarke's method of thematic  
4  
5 310 analysis.[39]

## 6 7 311 **ETHICS AND DISSEMINATION**

### 8 9 312 **Ethics**

10  
11 313 Ethical approval for the study has been granted by the University of Sydney Human Research Ethics  
12  
13 314 Committee (HREC), project numbers 2018/713 and 2019/308. Data collection and analysis will be  
14  
15 315 conducted in accordance with the Australian National Health and Medical Research Council National  
16  
17 316 Statement[41]. All participants will provide informed consent prior to taking part in the study.

### 18 19 317 **Data storage and protection**

20  
21 318 Participant privacy and confidentiality will be maintained by removing all identifying information  
22  
23 319 from the transcripts, by assigning pseudonyms to participants, and by storing study data securely on  
24  
25 320 password-protected computers or in locked filing cabinets within university premises, to which only  
26  
27 321 named researchers from the research team will have access. Deidentified interview transcripts will  
28  
29 322 be stored separately from the file containing participant identifiers. All data will be destroyed 7 years  
30  
31 323 after completion of the study in accordance with standard ethical guidelines around storage of study  
32  
31 324 data.

### 32 33 325 **Dissemination of study findings**

34  
35 326 Study findings will be disseminated via peer-reviewed journal publications, generalist publications,  
36  
37 327 presentations to the public, academics, clinicians, policymakers, melanoma consumers, and at  
38  
39 328 scientific conferences.

## 40 41 329 **SIGNIFICANCE AND IMPACT OF STUDY**

42  
43 330 This is the first multi-methods study to investigate the structural, contextual and cultural factors  
44  
45 331 impacting the implementation of national SLNB guidelines in Australia. The study will bring to light  
46  
47 332 the range of professional perspectives on SLNB, document the discourse surrounding SLNB in  
48  
49 333 Australia and report on how these may be affecting uptake of SLNB in patients with melanoma. The  
50  
51 334 knowledge generated by this project will be used to inform future efforts to support effective and  
52  
53 335 widespread melanoma guideline implementation in Australia and internationally. A greater  
54  
55 336 awareness of the guidelines, and the patients with melanoma to whom they apply, should in turn  
56  
57 337 lead to improved melanoma management and outcomes for patients, including more accurate  
58  
59 338 information about prognosis and access to adjuvant systemic therapies such as immunotherapy or  
60  
339 BRAF-directed targeted molecular therapy for eligible melanoma patients. And finally, the

1  
2  
3 340 knowledge generated in this study will focus attention on the role of SLNB as a diagnostic and  
4  
5 341 prognostic tool in melanoma, the role it has to play in accurate melanoma staging and cancer  
6  
7 342 registry reporting, and the role SLNB plays in the design and conduct of melanoma clinical trials both  
8  
9 343 now and in the future.

10 344 **Author statement**

11  
12  
13 345 **Acknowledgements** We thank Sam Robinson for help in preparing the ethics application.

14  
15 346 **Funding** This work was funded by the Melanoma Centre of Research Excellence grant (1135285)  
16  
17 347 from the Australian National Health and Medical Research Council. RLM received funding from an  
18  
19 348 NHMRC Translating Research into Practice (TRIP) Fellowship (1150989). AEC received a NHMRC  
20  
21 349 Career Development Fellowship (1147843) and Cancer Institute NSW Career Development  
22  
23 350 Fellowship (15/CDF/1-14).

24 351 **Competing interests** None.

25  
26 352 **Ethics approval** University of Sydney Human Research Ethics Committee, project numbers 2018/713  
27  
28 353 and 2019/308.

29  
30 354 **Provenance and peer review** Not commissioned; externally peer reviewed.

31  
32  
33 355 **Open Access** This is an Open Access article distributed in accordance with the Creative Commons  
34  
35 356 Attribution Non Commercial 4.0 international license (CC BY-NC 4.0), which permits others to  
36  
37 357 distribute, remix, adapt, build upon this work non-commercially, and license their derivative works  
38  
39 358 on different terms, provided the original work is properly cited and the use is non-commercial. See:  
40  
41 359 <http://creativecommons.org/licenses/by-nc/4.0/>

42 360 **Indirect Patient and Public Involvement**

43  
44 361 We did not directly include PPI in the design of this study, but the melanoma guidelines used in the  
45  
46 362 study were developed and updated by a committee that includes patient representatives.

47  
48 363 **REFERENCES**

49  
50 364

51  
52 365 1 Australian Institute of Health and Welfare (AIHW). *2018 Cancer Data in Australia; Australian*  
53  
54 366 *Cancer Incidence and Mortality (ACIM) books: melanoma of the skin*. AIHW  
55  
56 367 <<https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/>>

57 368

58  
59 369 2 Gershenwald JE, Scolyer RA, Hess KR, *et al*. Melanoma staging: evidence-based changes in the  
60

- 1  
2  
3 370 American Joint Committee on Cancer eighth edition cancer staging manual. *CA: A Cancer Journal for*  
4 371 *Clinicians* 2017;**67**:472–92. doi:10.3322/caac.21409  
5  
6 372  
7  
8 373 3 Mahul AB, Edge S, Greene F, *et al.* *AJCC Cancer Staging Manual*. 8th ed. Springer International  
9 374 Publishing 2017.  
10  
11 375  
12  
13 376 4 Gershenwald JE, Scolyer RA. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th  
14 377 edition and beyond. *Annals of Surgical Oncology* 2018;**25**:2105–10. doi:10.1245/s10434-018-6513-7  
15  
16 378  
17  
18 379 5 Morton D, Wen D, Wong J, *et al.* Technical details of intraoperative lymphatic mapping for early  
19 380 stage melanoma. *Archives of surgery (Chicago, Ill : 1960)* 1992;**127**:392–9.  
20  
21 381  
22  
23 382 6 Mitra A, Conway C, Walker C, *et al.* Melanoma sentinel node biopsy and prediction models for  
24 383 relapse and overall survival. *British Journal of Cancer* 2010;**103**:1229. doi:10.1038/sj.bjc.6605849  
25  
26 384  
27  
28 385 7 Morton R, Howard K, Thompson J. The cost-effectiveness of sentinel node biopsy in patients with  
29 386 intermediate thickness primary cutaneous melanoma. *Annals of Surgical Oncology* 2008;**16**:929.  
30 387 doi:10.1245/s10434-008-0164-z  
31  
32 388  
33  
34 389 8 Faries MB, Thompson JF, Cochran AJ, *et al.* Completion Dissection or Observation for Sentinel-  
35 390 Node Metastasis in Melanoma. *The New England Journal of Medicine* 2017;**376**:2211–22.  
36 391 doi:10.1056/NEJMoa1613210  
37  
38 392  
39  
40 393 9 Leiter U, Stadler R, Mauch C, *et al.* Complete lymph node dissection versus no dissection in  
41 394 patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre,  
42 395 randomised, phase 3 trial. *The Lancet Oncology* 2016;**17**:757–67. doi:10.1016/s1470-2045(16)00141-  
43 396 8  
44  
45 397  
46  
47 398 10 Shuchter L. Adjuvant Melanoma Therapy — Head-Spinning Progress. *The New England Journal of*  
48 399 *Medicine* 2017;**377**:1888–90. doi:10.1056/nejme1711199  
49  
50 400  
51  
52 401 11 Long GV, Hauschild A, Santinami M, *et al.* Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-  
53 402 Mutated Melanoma. *New Engl J Medicine* 2017;**377**:1813–23. doi:10.1056/nejmoa1708539  
54  
55 403  
56  
57  
58  
59  
60

- 1  
2  
3 404 12 Weber J, Mandala M, Vecchio M, *et al.* Adjuvant Nivolumab versus Ipilimumab in Resected Stage  
4  
5 405 III or IV Melanoma. *The New England Journal of Medicine* 2017;**377**:1824–35.  
6  
7 406 doi:10.1056/nejmoa1709030  
8  
9 407  
10 408 13 Eggermont A, Blank CU, Mandala M, *et al.* Adjuvant Pembrolizumab versus Placebo in Resected  
11  
12 409 Stage III Melanoma. *New Engl J Medicine* 2018;**378**:1789–801. doi:10.1056/nejmoa1802357  
13  
14 410  
15 411 14 Amin M, Greene FL, Edge SB, *et al.* The Eighth Edition AJCC Cancer Staging Manual: Continuing to  
16  
17 412 build a bridge from a population-based to a more “personalized” approach to cancer staging. *CA: A*  
18  
19 413 *Cancer Journal for Clinicians* 2017;**67**:93–9. doi:10.3322/caac.21388  
20  
21 414  
22 415 15 Gyorki D, Barbour A, Mar V, *et al.* Cancer Council Australia Melanoma Guidelines Working Party.  
23  
24 416 When is a sentinel node biopsy indicated? .  
25  
26 417 2019.[http://wiki.cancer.org.au/australia/Clinical\\_question:When\\_is\\_a\\_sentinel\\_node\\_biopsy\\_indica](http://wiki.cancer.org.au/australia/Clinical_question:When_is_a_sentinel_node_biopsy_indicated%3F)  
27  
28 418 [ted%3F](http://wiki.cancer.org.au/australia/Clinical_question:When_is_a_sentinel_node_biopsy_indicated%3F). (accessed 2019).  
29  
30 419  
31 420 16 Smithers MB, Hughes MB, Beesley VL, *et al.* Prospective study of patterns of surgical  
32  
33 421 management in adults with primary cutaneous melanoma at high risk of spread, in Queensland,  
34  
35 422 Australia. *Journal of Surgical Oncology* 2015;**112**:359–65. doi:10.1002/jso.24013  
36  
37 423  
38 424 17 Varey AH, Madronio CM, Cust AE, *et al.* Poor Adherence to National Clinical Management  
39  
40 425 Guidelines: A Population-Based, Cross-Sectional Study of the Surgical Management of Melanoma in  
41  
42 426 New South Wales, Australia. *Annals of Surgical Oncology* 2017;**24**:2080–8. doi:10.1245/s10434-017-  
43  
44 427 5890-7  
45  
46 428  
47 429 18 Silva E. Adjunct primer for the use of national comprehensive cancer network guidelines for the  
48  
49 430 surgical management of cutaneous malignant melanoma patients. *World journal of surgical oncology*  
50  
51 431 2012;**10**:54. doi:10.1186/1477-7819-10-54  
52  
53 432  
54 433 19 Grange F, Vitry F, Granel-Brocard F, *et al.* Variations in Management of Stage I to Stage III  
55  
56 434 Cutaneous Melanoma: A Population-Based Study of Clinical Practices in France. *Arch Dermatol*  
57  
58 435 2008;**144**:629–36. doi:10.1001/archderm.144.5.629  
59  
60 436  
61 437 20 Shah DR, Yang AD, Maverakis E, *et al.* Assessing rural–urban disparities in the use of sentinel

- 1  
2  
3 438 lymph node biopsy for melanoma. *J Surg Res* 2013;**184**:1157–60. doi:10.1016/j.jss.2013.04.091  
4  
5 439  
6  
7 440 21 Sant M, Minicozzi P, Allemani C, *et al.* Regional inequalities in cancer care persist in Italy and can  
8 441 influence survival. *Cancer Epidemiology* 2012;**36**:541–7. doi:10.1016/j.canep.2012.06.006  
9  
10 442  
11  
12 443 22 Hong NJ, Cheng SY, Baxter NN, *et al.* Melanoma patterns of care in Ontario: A call for a strategic  
13 444 alignment of multidisciplinary care. *Journal of Surgical Oncology* 2018;**117**:597–617.  
14 445 doi:10.1002/jso.24936  
15  
16 446  
17  
18 447 23 Rivard J, Kostaras X, Shea-Budgell M, *et al.* A population-based assessment of melanoma: Does  
19 448 treatment in a regional cancer center make a difference? *J Surg Oncol* 2015;**112**:173–8.  
20 449 doi:10.1002/jso.23981  
21  
22 450  
23  
24 451 24 Garreau JR, Nelson J, Cook D, *et al.* Geographic variation in sentinel node adaptation by practicing  
25 452 surgeons in Oregon. *Am J Surg* 2005;**189**:616–20. doi:10.1016/j.amjsurg.2005.01.039  
26  
27 453  
28  
29 454 25 Sharouni M-A, Witkamp AJ, Sigurdsson V, *et al.* Trends in Sentinel Lymph Node Biopsy Enactment  
30 455 for Cutaneous Melanoma. *Annals of Surgical Oncology* 2019;**26**:1494–502. doi:10.1245/s10434-019-  
31 456 07204-2  
32  
33 457  
34  
35 458 26 Dopson S, Locock L, Gabbay J, *et al.* Evidence-Based Medicine and the Implementation Gap.  
36 459 *Health*: 2003;**7**:311–30. doi:10.1177/1363459303007003004  
37  
38 460  
39  
40 461 27 Bosk CL, Dixon-Woods M, Goeschel CA, *et al.* Reality check for checklists. *The Lancet*  
41 462 2009;**374**:444–5. doi:10.1016/s0140-6736(09)61440-9  
42  
43 463  
44  
45 464 28 Greenhalgh T, Robert G, MacFarlane F, *et al.* Diffusion of Innovations in Service Organizations:  
46 465 Systematic Review and Recommendations. *Milbank Quarterly* 2004;**82**:581–629. doi:10.1111/j.0887-  
47 466 378x.2004.00325.x  
48  
49 467  
50  
51 468 29 Ferlie E, Gabbay J, Fitzgerald L, *et al.* Evidence-based medicine and organisational change: an  
52 469 overview of some recent qualitative research. In: *Organisational behaviour and organisational*  
53 470 *studies in health care: Reflections on the future*. Palgrave Macmillan 2001. 18–42.  
54  
55 471  
56  
57  
58  
59  
60


- 1  
2  
3 472 30 Rapport F, Hogden A, Faris M, *et al.* *Qualitative research in healthcare: modern methods, clear*  
4 *translation. A white paper.* Macquarie University 2018.  
5 473  
6 474  
7  
8 475 31 Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a  
9 476 32-item checklist for interviews and focus groups. *International Journal for Quality in Health Care*  
10 477 2007;**19**:349–57. doi:10.1093/intqhc/mzm042  
11  
12 478  
13  
14 479 32 von Elm E, Altman DG, Egger M, *et al.* The Strengthening the Reporting of Observational Studies  
15 480 in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. *Int J Surg*  
16 481 2014;**12**:1495–9. doi:10.1016/j.ijsu.2014.07.013  
17  
18 482  
19 483 33 Miles M, Huberman M. *Qualitative data analysis: An expanded sourcebook.* 1994.  
20 484 books.google.com  
21 485  
22 486 34 Charmaz K. *Constructing grounded theory: a practical guide through qualitative analysis.* 1st ed.  
23 487 SAGE Publications 2006.  
24  
25 488  
26 489 35 Harris PA, Taylor R, Thielke R, *et al.* Research electronic data capture (REDCap)—A metadata-  
27 490 driven methodology and workflow process for providing translational research informatics support. *J*  
28 491 *Biomed Inform* 2009;**42**:377–81. doi:10.1016/j.jbi.2008.08.010  
29  
30 492  
31 493 36 Australian Bureau of Statistics (ABS). *Socio-Economic Indexes for Areas (SEIFA).* ABS 2018.  
32 494 <http://www.abs.gov.au/websitedbs/censushome.nsf/home/seifa> (accessed 2019).  
33  
34 495  
35 496 37 Australian Bureau of Statistics (ABS). *The Australian Statistical Geography Standard (ASGS)*  
36 497 *remoteness structure.* ABS 2018.  
37 498 <http://www.abs.gov.au/websitedbs/d3310114.nsf/home/remoteness+structure13> (accessed 2019).  
38  
39 499  
40 500 38 Clarke V, Braun V. Thematic analysis. *J Posit Psychology* 2016;;1–2.  
41 501 doi:10.1080/17439760.2016.1262613  
42  
43 502  
44 503 39 Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative Research in Psychology*  
45 504 2006;**3**:77–101. doi:10.1191/1478088706qp063oa  
46  
47 505  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

506 40 Bowen G. Document analysis as a qualitative research method. *Qualitative research journal*  
507 Published Online First: 2009. doi:10.3316/QRJ0902027  
508  
509 41 The National Health and Medical Research Council, the Australian Research Council and  
510 Universities Australia (NHMRC). *National Statement on Ethical Conduct in Human Research 2007*  
511 *(Updated 2018)*. Commonwealth of Australia 2018.  
512

For peer review only

# Preliminary mapping exercise: melanoma care continuum / CRE in Melanoma activities




bmjopen-2019-02636 on 27 February 2020. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46




# Preliminary mapping exercise: melanoma care continuum / CRE in Melanoma activities

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46



# Preliminary mapping exercise: melanoma care continuum / CRE in Melanoma activities




CRUJENT / PROPOSED  
CORE 3 CRE ACTIVITIES

bmjopen-2019-02636 on 27 February 2020. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

# Preliminary mapping exercise: melanoma care continuum / CRE in Melanoma activities



bmjopen-2019-02636 on 27 February 2020. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

# Preliminary mapping exercise: melanoma care continuum / CRE in Melanoma activities



bmjopen-2019-02636 on 27 February 2020 downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46



THE UNIVERSITY OF  
**SYDNEY**



**Melanoma**  
Centre of Research Excellence

**Cancer Epidemiology and Prevention Research**  
**School of The University of Sydney**  
**Faculty of Medicine and Health**

## Melanoma management survey for GPs

1. What best describes the type of practice you work in?

- Independent GP practice
- Medical centre practice
- Skin cancer clinic
- Other (please specify): \_\_\_\_\_

2. What is the postcode or suburb/town of your practice? \_\_\_\_\_

3. What is your gender?

- Female
- Male

4. What is your age?

- < 30 years
- 30-39 years
- 40-49 years
- 50-59 years
- 60-69 years
- 70+ years

5. How many patients would you usually see with invasive melanoma in one year (i.e. not including melanoma in situ/lentigo maligna)?

- None
- 1 patient per year
- 2-5 patients per year
- 6-10 patients per year
- 11-30 patients per year
- >30 patients per year

6. How many years have you been practising as a GP?

- <5 years
- 6-10 years
- 11-20 years
- 21-30 years
- 31-40 years
- >40 years

7. On a scale of 1 to 5, how familiar are you with the national clinical practice guidelines for melanoma management? **(tick one only)**

- 1 - Very unfamiliar
- 2 - Somewhat unfamiliar
- 3 - A little familiar
- 4 - Quite familiar
- 5 - Very familiar

Melanoma management study, GP survey

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

8. Have you accessed the recent update of the national clinical practice guidelines for melanoma on the Cancer Council Australia website/Wiki?

- No  
 Yes

9. Have you read any articles (e.g. in journals, magazines, newsletters) or listened to talks about sentinel lymph node biopsy (SLNB) for melanoma in the last 3 years?

- No → go to question 11  
 Yes → **tick all that apply**
- Australian Family Physician
  - Australian Journal of General Practice (AJGP)
  - Medical Journal of Australia (MJA)
  - Other peer-reviewed journal, please specify: \_\_\_\_\_
  - Newspaper
  - Conference lecture
  - Workshop or seminar
  - Other, please specify \_\_\_\_\_

10. Do you think these articles or presentations have influenced your attitude to sentinel lymph node biopsy for melanoma?

- No  
 Yes → How have they influenced you? \_\_\_\_\_

11. Do you think that sentinel lymph node biopsy has an important role in the management of melanoma patients?

- No → Why not? \_\_\_\_\_  
 Yes  
 Unsure

12. Would you usually discuss and recommend sentinel lymph node biopsy to a patient with a newly diagnosed melanoma, if eligible for sentinel lymph node biopsy?

- No → go to question 21  
 Yes → go to question 13

13. Why do you believe that sentinel lymph node biopsy may be of value? (**tick all that apply**)

- More accurate staging and prognostic information  
 Likely survival benefit  
 Influence of the results on patient management  
 To assess suitability for adjuvant systemic therapies for melanoma patients who are found to be sentinel lymph node positive  
 To select patients for completion lymphadenectomy  
 Other (please specify): \_\_\_\_\_

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

14. At what Breslow thickness or other criteria would you tell a patient that sentinel lymph node biopsy would be appropriate? **(tick all that apply)**

- <0.80 mm
- <0.80 mm and other high-risk pathological feature/s
- 0.80 - 1.00 mm
- 0.80 - 1.00 mm and other high-risk pathological feature/s
- 1.01 - 2.00 mm
- 2.01 - 4.00 mm
- >4.00 mm
- Other criteria, please specify \_\_\_\_\_

15. Would any of these factors influence your decision to discuss or recommend sentinel lymph node biopsy to patients? **(tick all that apply)**

- Breslow thickness
- Presence of ulceration
- Mitotic rate of the melanoma
- Lymphovascular invasion in the melanoma
- Body site of the melanoma
- Presence of palpable regional lymph nodes
- Histological subtype, e.g. superficial spreading, nodular, lentigo maligna melanoma
- Age of the patient
- Comorbidities of the patient
- The morbidity of the sentinel lymph node biopsy procedure
- The morbidity of completion lymphadenectomy
- The likelihood that the results will influence patient management
- Access to services for sentinel lymph node mapping and biopsy
- Distance to services for sentinel lymph node mapping and biopsy
- Costs to the patient
- Patient level of anxiety
- Patient preference
- Other, please specify \_\_\_\_\_

16. For patients for whom sentinel lymph node biopsy would be suitable, who would you usually refer the patient to for definitive management? **(tick one only)**

- A local general surgeon
- Any surgical oncologist
- A melanoma-trained surgical oncologist
- Any plastic surgeon
- A melanoma trained plastic surgeon
- A Skin Cancer Clinic colleague
- Any Dermatologist
- A melanoma specialist dermatologist
- A specialist melanoma service where there is a multidisciplinary team
- Other, please specify: \_\_\_\_\_

1  
2  
3 17. Would you expect the clinician to whom you refer the patient, to recommend a sentinel lymph node  
4 biopsy if they were eligible? **(tick one only)**

- 5  No, never  
6  Occasionally  
7  Most of the time  
8  Yes, always  
9

10  
11 18. After a negative sentinel lymph node biopsy, are you wanting to be involved in ongoing patient follow-  
12 up? **(tick one only)**

- 13  No  
14  Yes, with follow-up managed mainly by myself  
15  Yes, with follow-up managed mainly by the specialist  
16  Yes, with follow-up managed in a shared care arrangement between the specialist and myself  
17

18 19. After a positive sentinel lymph node biopsy, are you wanting to be involved in ongoing patient follow-  
19 up? **(tick one only)**

- 20  No  
21  Yes, with follow-up managed mainly by myself  
22  Yes, with follow-up managed mainly by the specialist  
23  Yes, with follow-up managed in a shared care arrangement between the specialist and myself  
24  
25

26 20. Are there any tests or scans that you would arrange for patients eligible for sentinel lymph node  
27 biopsy? **(tick all that apply)**

- 28  No other tests or scans  
29  Ultrasound examination of regional nodes  
30  Chest X ray  
31  CT Chest/abdomen/pelvis  
32  Whole body PET-CT  
33  CT or MRI scan of brain  
34  Other, please specify: \_\_\_\_\_  
35  
36

37 → Please go to question 22  
38  
39

40 *[Note Question 21 is only for those who selected 'No' at Question 12]*  
41  
42

43 21. Why would you not usually recommend sentinel lymph node biopsy? **(tick all that apply)**

- 44  Don't know much about it  
45  Difficulty in accessing facilities for sentinel lymph node biopsy  
46  No confirmed survival benefit  
47  Does not add sufficient additional prognostic information  
48  Does not impact subsequent management  
49  The morbidity of the procedure  
50  The morbidity of completion lymphadenectomy if the sentinel node is positive  
51  Costs to the patient  
52  Other, please specify: \_\_\_\_\_  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

22. Would you be willing to be contacted by the research team for a 20 minute confidential interview to discuss risk factors, diagnosis and management of patients with melanoma by general practitioners?

We would reimburse your time with a \$100 Coles/Myer gift voucher.

- Yes → Please enter your contact details below and ask the research team for a Participant Information Sheet and Consent form for the interview study. Your contact details will be stored separately to your survey and interview data.
- No → continue to next page

Your Name: \_\_\_\_\_

Best contact phone number: \_\_\_\_\_

Email address: \_\_\_\_\_

Best time and/or day of the week: \_\_\_\_\_

*Continue to next page*

For peer review only

1  
2 23. Would you like to receive a summary of the results of this study after it has been completed, in about 1  
3 year's time?

4  Yes → please enter your email address: \_\_\_\_\_.

5 Your email address will not be linked to your survey responses and will be stored separately.

6  
7  No

8  
9  
10  
11 24. Please enter your email address if you would like to go into a lucky draw to win one of three iPads. The  
12 draw will take place when recruitment to the study is complete.

13 Email address: \_\_\_\_\_

14 Your email address will not be linked to your survey responses and will be stored separately.

15  
16  
17  
18 *You have completed the questionnaire! Thank you very much for your time.*

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## Melanoma management survey for Dermatologists

1. What best describes the type of practice you work in?

- Independent specialist practice
- Dermatology group specialist practice
- Melanoma Unit
- Other (please specify): \_\_\_\_\_

2. What is the postcode or suburb/town of your practice? \_\_\_\_\_

3. What is your gender?

- Female
- Male

4. What is your age?

- < 30 years
- 30-39 years
- 40-49 years
- 50-59 years
- 60-69 years
- 70+ years

5. How many patients would you usually see with invasive melanoma in one year (i.e. not including melanoma in situ/lentigo maligna)?

- None
- 1 patient per year
- 2-4 patients per year
- 6-10 patients per year
- 11-30 patients per year
- >30 patients per year

1 6. How many years have you been practising as a Dermatologist?  
2

- 3  <5 years  
4  6-10 years  
5  11-20 years  
6  21-30 years  
7  31-40 years  
8  >40 years  
9

10 7. On a scale of 1 to 5, how familiar are you with the Australian “Clinical Practice Guidelines for the  
11 Diagnosis and Management of Melanoma”?  
12

13 **(tick ONE only)**

- 14  1 - Very unfamiliar  
15  2 - Somewhat unfamiliar  
16  3 - A little familiar  
17  4 - Quite familiar  
18  5 - Very familiar  
19

20 8. Have you accessed the recent update of the Australian “Clinical Practice Guidelines for the Diagnosis and  
21 Management of Melanoma” on the Cancer Council Australia website/Wiki?  
22

- 23  No  
24  Yes  
25

26 9. Have you read any articles (e.g. in journals, magazines, newsletters) or listened to talks about sentinel  
27 lymph node biopsy (SLNB) for melanoma in the last 3 years?  
28

- 29  No → go to question 11  
30  Yes → **tick ALL that apply**  
31  Australasian Journal of Dermatology  
32  Medical Journal of Australia (MJA)  
33  Journal of the American Academy of Dermatology (JAAD)  
34  British Journal of Dermatology (BJD)  
35  New England Journal of Medicine (NEJM)  
36  Other peer-reviewed journal, please specify: \_\_\_\_\_  
37  Australian Conference  
38  International Conference  
39  Other, please specify \_\_\_\_\_  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

58 10. Do you think these articles or presentations have influenced your attitude to sentinel lymph node  
59 biopsy for melanoma?  
60

- 1  No  
2  
3  Yes – more likely to recommend SLNB  
4  
5  Yes – less likely to recommend SLNB  
6

7 How have they influenced you? \_\_\_\_\_  
8  
9

10 11. Do you think that sentinel lymph node biopsy has an important role in the management of melanoma  
11 patients?  
12

- 13  No → Why not? \_\_\_\_\_  
14  
15  Yes  
16  
17  Unsure → Why not? \_\_\_\_\_  
18

19  
20  
21 12. Would you usually discuss and recommend sentinel lymph node biopsy to a patient with a newly  
22 diagnosed melanoma, if eligible for sentinel lymph node biopsy?  
23

- 24  No → go to question 13  
25  
26  Yes → go to question 14  
27

28  
29 **[Note Question 13 is only for those who selected 'NO' at Question 12]**  
30

31 13. Why would you not usually recommend sentinel lymph node biopsy?  
32

33 **(tick ALL that apply)**  
34

- 35  Don't know much about it  
36  
37  No added value of sentinel lymph node biopsy  
38  
39  Difficulty in accessing facilities for sentinel lymph node biopsy  
40  
41  No confirmed overall survival benefit  
42  
43  Does not add additional prognostic information beyond what is provided by Breslow thickness  
44  
45  Does not impact subsequent management  
46  
47  The morbidity of the procedure  
48  
49  The morbidity of completion lymphadenectomy if the sentinel node is positive  
50  
51  Costs to the patient  
52  
53  Other, please specify: \_\_\_\_\_  
54

55 **Continue to Question 23 [page 6]**  
56  
57  
58  
59  
60

1 **[Note Question 14 is only for those who selected 'YES' at Question 12]**

2  
3 14. Why do you believe that sentinel lymph node biopsy may be of value for eligible patients?

4  
5 **(tick ALL that apply)**

- 6  More accurate staging
- 7
- 8  To provide prognostic information
- 9
- 10  Likely survival benefit
- 11
- 12  Results may influence follow-up plan
- 13
- 14  To assess suitability for adjuvant systemic therapies if found to be sentinel lymph node positive
- 15
- 16  To select patients for completion lymphadenectomy
- 17
- 18  Improved regional control
- 19
- 20  Other (please specify): \_\_\_\_\_
- 21
- 22

23 15. At what Breslow thickness would you advise a patient that sentinel lymph node biopsy would be  
24 appropriate and refer them to a surgeon for management?

25  
26 **(tick ALL that apply)**

- 27
- 28  <0.80 mm
- 29
- 30  <0.80 mm with high-risk pathological feature/s
- 31
- 32  0.80 - 1.00 mm
- 33
- 34  0.80 - 1.00 mm with high-risk pathological feature/s
- 35
- 36  1.01 - 2.00 mm
- 37
- 38  2.01 - 4.00 mm
- 39
- 40  >4.00 mm
- 41
- 42  None of the above (I would not refer for SLNB)
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1 16. Would any of these factors influence your decision to discuss or recommend sentinel lymph node  
2 biopsy to patients?  
3

4 **(tick ALL that apply)**

- 5  Breslow thickness
- 6  Presence of ulceration
- 7  Mitotic rate of the melanoma
- 8  Lymphovascular invasion in the melanoma
- 9  Body site of the melanoma
- 10  Wide excision already performed
- 11  Type of wound closure following diagnostic biopsy
- 12  Presence of palpable regional lymph nodes
- 13  Histological subtype, e.g. desmoplastic, nodular, lentigo maligna melanoma
- 14  Age of the patient
- 15  Comorbidities of the patient
- 16  Possible morbidity of the sentinel lymph node biopsy procedure
- 17  Possible morbidity of completion lymphadenectomy
- 18  The likelihood that the results will influence patient management
- 19  Access to services for sentinel lymph node mapping and biopsy
- 20  Distance to services for sentinel lymph node mapping and biopsy
- 21  Costs to the patient
- 22  Patient level of anxiety
- 23  Patient preference
- 24  Other, please specify \_\_\_\_\_

25 17. For patients for whom sentinel lymph node biopsy would be suitable, who would you usually refer the  
26 patient to for definitive management?  
27

28 **(tick ONE only)**

- 29  A local general surgeon
- 30  Any surgical oncologist
- 31  A melanoma-trained surgical oncologist
- 32  Any plastic surgeon
- 33  A melanoma-trained plastic surgeon
- 34  A melanoma specialist dermatologist
- 35  A specialist melanoma service where there is a multidisciplinary team
- 36  None of the above (I would not refer for SLNB)

- 1            Other, please specify: \_\_\_\_\_

2  
3 18. Would you expect the clinician to whom you refer the patient to recommend a sentinel lymph node  
4 biopsy if they were eligible?

5  
6 **(tick ONE only)**

- 7            No, never  
8  
9            Occasionally  
10  
11            Most of the time if appropriate for the patient's situation  
12  
13            Yes, always  
14  
15            I would not refer to a surgeon who routinely recommends SLNB  
16

17 19. After a negative sentinel lymph node biopsy for melanoma, do you wish to be involved in ongoing  
18 patient follow-up for recurrence?

19  
20 **(tick ONE only)**

- 21            No  
22  
23            Yes, with follow-up managed mainly by myself  
24  
25            Yes, with follow-up managed mainly by the surgeon  
26  
27            Yes, with follow-up managed in a shared care arrangement between the surgeon and myself  
28  
29

30 20. After a positive sentinel lymph node biopsy for melanoma, do you wish to be involved in ongoing  
31 patient follow-up for recurrence?

32  
33 **(tick ONE only)**

- 34            No  
35  
36            Yes, with follow-up managed mainly by myself  
37  
38            Yes, with follow-up managed mainly by the surgeon or medical oncologist  
39  
40            Yes, with follow-up managed in a shared care arrangement between the surgeon or medical  
41 oncologist and myself  
42

43 21. Are there any tests or scans that you would arrange for patients eligible for sentinel lymph node biopsy  
44 at the time of diagnosis?

45  
46 **(tick ALL that apply)**

- 47            No other tests or scans  
48  
49            Ultrasound examination of regional nodes  
50  
51            Chest X ray  
52  
53            CT chest/abdomen/pelvis  
54  
55            Whole body PET-CT  
56  
57            CT or MRI scan of brain  
58  
59            Other, please specify: \_\_\_\_\_  
60



1 22. Are there any tests or scans that you would arrange for follow-up of patients diagnosed with melanoma  
2 >1 mm?  
3

4 **(tick ALL that apply)**

- 5  No other tests or scans  
6  
7  Ultrasound examination of regional nodes  
8  
9  Chest X ray  
10  
11  CT chest/abdomen/pelvis  
12  
13  Whole body PET-CT  
14  
15  CT or MRI scan of brain  
16  
17  Other, please specify: \_\_\_\_\_  
18  
19  
20  
21  
22  
23  
24

25 *Continue to next page*  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

ID number: \_\_\_\_\_

1 23. Would you like to receive a summary of the results of this study after it has been completed, in about 1  
2 years' time?  
3

4  Yes → please enter your email address: \_\_\_\_\_  
5

6 *Your email address will not be linked to your survey responses and will be stored separately.*  
7

8  No  
9

10 24. Would like to go into a lucky draw to win one of three iPads? The draw will take place when recruitment  
11 to the study is complete.  
12

13  Yes → please enter your email address: \_\_\_\_\_  
14

15 *Your email address will not be linked to your survey responses and will be stored separately.*  
16

17  No  
18

19 25. Would you be willing to be contacted by the research team for a 20-minute confidential interview to  
20 discuss risk factors, diagnosis and management of patients with melanoma by dermatologists? We would  
21 reimburse your time with a \$100 Coles/Myer gift voucher.  
22

23  Yes → Please enter your contact details below and ask the research team for a Participant  
24 Information Sheet and Consent form for the interview study. Your contact details will be stored  
25 separately to your survey and interview data.  
26

27  No  
28

29  
30 Your Name: \_\_\_\_\_  
31

32  
33  
34 Best contact phone number: \_\_\_\_\_  
35

36  
37  
38 Email address: \_\_\_\_\_  
39

40  
41  
42 Best time and/or day of the week: \_\_\_\_\_  
43

44  
45 ***You have completed the questionnaire! Thank you very much for your time.***  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: a protocol paper for a mixed methods study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032636.R1
Article Type:	Protocol
Date Submitted by the Author:	24-Dec-2019
Complete List of Authors:	Rapport, Frances ; Macquarie University, Australian Institute of Health Innovation Smith, Andrea; Macquarie University, Australian Institute of Health Innovation Cust, Anne; The University of Sydney, Sydney Medical School Mann, Graham; University of Sydney, Western Clinical School, Westmead Millenium Institute Watts, Caroline; University of Sydney, Sydney School of Public Health Gyorki, David; Peter MacCallum Cancer Centre Henderson, Michael; Peter MacCallum Cancer Institute, Cancer Surgery Hong, Angela; Melanoma Institute Australia Kelly, John; Alfred Health, Victorian Melanoma Service Long, Georgina; Melanoma Institute Australia Mar, Victoria; Alfred Health, Victorian Melanoma Service Morton, Rachael; NHMRC Clinical Trials Centre Saw, Robyn; Melanoma Institute Australia Scolyer, Richard; University of Sydney, Sydney Medical School Spillane, Andrew; Melanoma Institute Australia Thompson, John ; Melanoma Institute Australia Braithwaite, Jeffrey; Macquarie University, Australian Institute of Health Innovation
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Dermatology
Keywords:	QUALITATIVE RESEARCH, melanoma, sentinel lymph node biopsy, implementation science, systemic adjuvant therapy, Dermatological tumours < ONCOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**TITLE**

Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: a protocol paper for a mixed methods study

**Authors:** Frances Rapport,<sup>\*1</sup> Andrea L Smith,<sup>\*1</sup> Anne E Cust,<sup>2,3</sup> Graham J Mann,<sup>3,4</sup> Caroline G Watts,<sup>2,5</sup> David E Gyorki,<sup>6</sup> Michael Henderson,<sup>6</sup> Angela M Hong,<sup>3,7</sup> John W Kelly,<sup>8</sup> Georgina V Long,<sup>3,7</sup> Victoria J Mar,<sup>8</sup> Rachael L Morton,<sup>3,9</sup> Robyn PM Saw,<sup>3,7</sup> Richard A Scolyer,<sup>3,7</sup> Andrew J Spillane,<sup>3,7</sup> John F Thompson,<sup>3,7</sup> Jeffrey Braithwaite<sup>1</sup>

\* These authors contributed equally to this work.

<sup>1</sup> Faculty of Medicine and Health Sciences, Australian Institute of Health Innovation, Macquarie University, Sydney, Australia

<sup>2</sup> Cancer Epidemiology and Prevention Research, Sydney School of Public Health, The University of Sydney, Australia

<sup>3</sup> Melanoma Institute Australia The University of Sydney, Sydney, Australia

<sup>4</sup> The John Curtin School of Medical Research, ANU, Canberra, Australia

<sup>5</sup> Surveillance, Epidemiology and Prevention Program, Kirby Institute, UNSW, Sydney, Australia

<sup>6</sup> Peter MacCallum Cancer Centre, Melbourne, Australia

<sup>7</sup> Faculty of Medicine and Health, The University of Sydney, Sydney, Australia

<sup>8</sup> Victorian Melanoma Service, The Alfred Hospital, Melbourne, Australia

<sup>9</sup> NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

**Correspondence to** Andrea L Smith: [andrea.smith@mq.edu.au](mailto:andrea.smith@mq.edu.au)

**Journal:** BMJ Open

**Word count** 3498 (excluding Abstract, Article Summary, tables and boxes, acknowledgements and references)

**Keywords** Mixed methods; melanoma; sentinel lymph node biopsy; implementation science; systemic adjuvant therapy; clinical practice guidelines

## 1 ABSTRACT

2 **Introduction:** Sentinel lymph node biopsy (SLNB) is a diagnostic procedure developed in the 1990s. It  
3 is currently used to stage patients with primary cutaneous melanoma, provide prognostic  
4 information and guide management. The Australian Clinical Practice Guidelines state that SLNB  
5 should be considered for patients with cutaneous melanoma >1mm in thickness (or >0.8mm with  
6 high-risk pathology features). Until recently, SLN status was used to identify patients who might  
7 benefit from a completion lymph node dissection, a procedure that is no longer routinely  
8 recommended. SLN status is now also being used to identify patients who might benefit from  
9 systemic adjuvant therapies such as anti-PD1 checkpoint inhibitor immunotherapy or BRAF-directed  
10 molecular targeted therapy, treatments that have significantly improved relapse-free survival for  
11 patients with resected stage III melanoma and improved overall survival of patients with  
12 unresectable stage III and stage IV melanoma. Australian and international data indicate that  
13 approximately half of eligible patients receive a SLNB.

14 **Methods and analysis:** This mixed-methods study seeks to understand the structural, contextual and  
15 cultural factors affecting implementation of the SLNB guidelines. Data collection will include: (1)  
16 cross-sectional questionnaires and semi-structured interviews with general practitioners and  
17 dermatologists; (2) semi-structured interviews with other healthcare professionals involved in the  
18 diagnosis and early definitive care of melanoma patients, and key stakeholders including  
19 researchers, representatives of professional colleges, training organisations, and consumer  
20 melanoma groups; and (3) documentary analysis of documents from government, health services  
21 and non-government organisations. Descriptive analyses and multivariable regression models will be  
22 used to examine factors related to SLNB practices and attitudes. Qualitative data will be analysed  
23 using thematic analysis.

24 **Ethics and dissemination:** Ethics approval has been granted by the University of Sydney. Results will  
25 be disseminated through publications and presentations to clinicians, patients, policymakers and  
26 researchers, and will inform the development of strategies for implementing SLNB guidelines in  
27 Australia.

### 32 **Strengths and limitations of this study**

33 The mixed-method design, comprising cross-sectional questionnaires, in-depth interviews and  
34 documentary analysis, will generate rich data about the determinants of SLNB guideline  
35 implementation.

36 The TICD Checklist will be used to identify the determinants of implementation (that is, the barriers  
37 and enablers of implementation).

38 The TICD Checklist will also help to inform possible implementation strategies that could be used to  
39 address some of these barriers to implementation of the SLNB guidelines.

40 The purposive recruitment of healthcare professionals and stakeholders, and the sampling and  
41 selection of documents and policies, may introduce selection biases.

## 42 **INTRODUCTION**

### 43 *Centre of Research Excellence in Melanoma*

44 The Centre of Research Excellence (CRE) in Melanoma is an Australian collaboration of clinicians,  
45 researchers and implementation scientists from melanoma centres and universities in New South  
46 Wales (Melanoma Institute Australia; The University of Sydney; and the Australian Institute of Health  
47 Innovation, Macquarie University) and Victoria (Peter MacCallum Cancer Centre; Victorian  
48 Melanoma Service Alfred Hospital; The University of Melbourne; Monash University and the Skin  
49 and Cancer Foundation), Australia, and is funded by the Australian National Health and Medical  
50 Research Council (NHMRC). The Melanoma CRE, like all Australian government-funded CREs, is  
51 tasked with three primary objectives: pursuing collaborative research; developing capacity; and  
52 promoting translation of research outcomes into policy and practice. This third objective is the focus  
53 of the mixed-methods study outlined in this protocol paper, in particular to understand the  
54 structural, contextual and cultural factors affecting implementation of the recently updated national  
55 clinical practice guidelines for SLNB for melanoma patients in Australia.

### 56 *Prioritisation of SLNB uptake as a key implementation goal*

57 One of the rationales behind embedding implementation science expertise within the Melanoma  
58 CRE is to support the transfer of evidence-based, effective and efficient patient-centred care across  
59 and beyond the Melanoma CRE research sites so that all melanoma patients, regardless of location  
60 in Australia, can benefit from its generation of knowledge. A necessary first step in the  
61 implementation process is to identify and prioritise interventions with the greatest potential to



62 impact positively on the quality of care for patients with melanoma. Between December 2018 and  
 63 February 2019, meetings of Melanoma CRE members systematically mapped CRE projects across the  
 64 melanoma care continuum (Supplementary file 1) and identified two in which implementation  
 65 science had the greatest potential to identify pathways to practice change. One of these, 'SLNB for  
 66 patients with melanoma', is outlined in this protocol paper.

### 67 *Melanoma diagnosis and staging*

68 Melanoma is the fourth most common cancer diagnosis in Australia.<sup>1</sup> In 2019, it is estimated that  
 69 15,229 people will be diagnosed with invasive melanoma and that 1,725 people will die from it.<sup>1</sup>  
 70 Between 2011 and 2015, an individual diagnosed with melanoma had a 91% chance of surviving for  
 71 5 years.<sup>1</sup> Survival is influenced by the stage of the melanoma at diagnosis. Staging takes into account  
 72 tumour thickness and ulceration and whether the melanoma has spread regionally (to the lymph  
 73 nodes) or more distantly (to other parts of the body) (Table 1).<sup>2,3</sup> Accurate staging is a fundamental  
 74 prerequisite for optimal melanoma management. From the perspective of the individual patient,  
 75 staging provides important prognostic information, guides management and clinical decision-  
 76 making, including whether a patient may benefit from adjuvant systemic therapy, shapes  
 77 communication between the patient, their clinician, and the patient's family and may determine the  
 78 patient's eligibility for clinical trials.<sup>4</sup> From a public health perspective, staging also facilitates  
 79 standardised reporting, centralised cancer registry reporting, the design and conduct of clinical trials,  
 80 and the analysis of clinical trial data.<sup>2</sup>

81 **Table 1. Staging categories for cutaneous melanoma**

Stage	Definition
Stage 0	The melanoma is confined to the cells in the top layer of the skin (epidermis) and has not invaded the deeper layers (dermis); also known as <i>in situ</i> melanoma (in contrast to stages I to IV, which are referred to as invasive melanoma)
Stage I	The melanoma has not spread beyond the primary site (i.e. no metastases or lymph node involvement); the melanoma is: <ul style="list-style-type: none"> <li>• ≤ 2mm in thickness <u>without</u> ulceration</li> <li>• ≤ 1mm in thickness <u>with</u> ulceration</li> </ul>
Stage II	The melanoma has not spread beyond the primary site (i.e. no metastases or lymph node involvement); the melanoma is: <ul style="list-style-type: none"> <li>• &gt; 2mm in thickness <u>without</u> ulceration</li> <li>• &gt; 1mm in thickness <u>with</u> ulceration</li> </ul>
Stage III	The melanoma can be any thickness and locoregional metastasis is present (i.e. satellite, in-transit or microsatellite metastases or nodal metastases)

Stage	Definition
Stage IV	The melanoma can be any thickness and has spread to distant lymph nodes and organs e.g. lungs, liver, brain or bone

82 Adapted from AJCC 8<sup>th</sup> edition staging guidelines<sup>2,3</sup>

83 *SLNB*

84 An important primary melanoma staging tool is SLNB, a multiphase procedure involving cutaneous  
85 lymphatic mapping with lymphoscintigraphy in the nuclear medicine department, surgical removal  
86 of the localised SLNs, and pathological assessment of the SLNs for the presence of metastatic  
87 disease. The procedure has a high degree of accuracy for identifying patients with melanoma who  
88 have clinically occult metastases in their regional lymph nodes.<sup>5,6</sup>

89 Prior to the introduction of SLNB by Morton *et al.* in 1992,<sup>5</sup> the only way to detect spread  
90 from the primary tumour site to the regional lymph nodes was through clinical examination of the  
91 patient's lymph nodes or by performing an elective lymph node dissection with its attendant  
92 morbidity. Elective lymph node dissection was routinely offered to patients who were considered to  
93 be at risk of relapse in the belief that removal of all lymph nodes in the lymph node field would  
94 prevent distant spread of the melanoma to other parts of the body. However, as only a small  
95 proportion (about 20%) of those at-risk patients who had an elective lymph node dissection actually  
96 had nodal metastases, the procedure resulted in considerable unnecessary morbidity, primarily  
97 lymphoedema.

98 SLNB avoided this unnecessary morbidity by using nuclear medicine and vital blue dyes to  
99 identify the SLN, that is, the lymph node receiving direct lymphatic drainage from the primary  
100 melanoma site.<sup>5</sup> The rationale (which Morton referred to as the incubator hypothesis or step-wise  
101 model of disease progression) was that the most likely site of early metastases, the SLN, could then  
102 be removed and tested pathologically for clinically occult melanoma cells and, if found, a completion  
103 lymph node dissection performed. Conversely, if the SLN was clear of metastatic disease, then it was  
104 reasoned that it was unlikely that other, more distant nodes would be diseased, thereby saving the  
105 patient from an unnecessary lymph node dissection. In this context, SLNB has been reported to be  
106 cost-effective for the management of intermediate-thickness melanoma.<sup>7</sup>

### 107 *Contemporary melanoma management*

108 Based on the results of two recent randomised controlled trials,<sup>8,9</sup> it is now widely accepted that a  
109 completion lymph node dissection in patients who are SLN-positive does not provide an overall  
110 survival benefit. Consequently, the role SLNB plays in contemporary melanoma management is

1  
2  
3 111 changing. In Australia and in many other countries, in addition to providing staging and prognostic  
4 112 information, SLNB is now being used to identify patients who might benefit from adjuvant systemic  
5 113 therapy. Adjuvant systemic therapies, such as immunotherapies (in which the patient's own immune  
6 114 system is activated to target cancer cells) and BRAF-directed targeted molecular therapies (which  
7 115 block the growth and spread of cancer by interfering with specific abnormal molecules within the  
8 116 tumour cells themselves), have been developed on the basis of recent advances in our  
9 117 understanding of the molecular and immune biology of melanoma. These adjuvant systemic  
10 118 therapies have been shown to significantly prolong survival in patients with unresectable stage III  
11 119 and stage IV melanoma<sup>10</sup> and have also been shown to improve recurrence-free survival when  
12 120 administered as adjuvant therapy in patients with resected stage III melanoma.<sup>11-13</sup> However, they  
13 121 are not yet publicly funded in the adjuvant melanoma setting in Australia. Consequently, access is  
14 122 often restricted to clinical trials, eligibility for which requires staging via SLNB, and compassionate  
15 123 access schemes.

#### 124 *International (AJCC staging system) and national (Australian) guidelines for SLNB*

125 The American Joint Committee on Cancer (AJCC) Staging Manual has become the benchmark for  
126 classifying patients' disease stage, outlining prognosis, and establishing the best treatment  
127 approaches.<sup>14</sup> The recently updated eighth edition recommends that lymphatic mapping and SLNB  
128 should be routinely used as a staging procedure for patients with T1b, T2, T3 or T4 primary  
129 cutaneous melanomas (i.e. melanomas  $\geq 0.8$ mm with or without ulceration, or  $< 0.8$ mm with  
130 ulceration) and who have clinically negative regional lymph nodes.<sup>3</sup> Likewise, the 2018 Australian  
131 Clinical Practice Guidelines for the Diagnosis and Management of Melanoma recommend that 'SLNB  
132 should be considered for all patients with melanoma  $> 1$ mm in thickness and for patients with  
133 melanoma  $> 0.8$ mm with other high risk pathological features to provide optimal staging and  
134 prognostic information and to maximise management options for patients who are node positive.'<sup>15</sup>

#### 135 *Rates of SLNB in Australia and internationally*

136 The limited data that exist for rates of SLNB for melanoma in Australia indicate that these rates may  
137 be lower than expected.<sup>a</sup> A population-based study in Queensland between 2010 and 2014 reported  
138 rates of SLNB of 33% (261 of 787 study patients) for stage 1b and stage 2 melanoma patients.<sup>16</sup> The  
139 2006 New South Wales Melanoma Patterns of Care Study reported that SLNB was performed in 45%

---

<sup>a</sup> Rates of SLNB are likely to be related to the guidelines in place at that point in time. In Australia the 1999 guidelines stated 'Lymphatic mapping and sentinel node biopsy should be considered for all melanomas  $> 1$ mm thick provided they can be done in the context of a controlled clinical trial and by surgeons trained in these procedures'; the 2008 guidelines stated 'Patients with a melanoma  $> 1.0$ mm in thickness should be given the opportunity to discuss sentinel lymph node biopsy to provide staging and prognostic information'.

1  
2  
3 140 of patients diagnosed with a melanoma >0.75mm thick.<sup>17</sup> SLNB rates in Australia are roughly  
4  
5 141 comparable to rates reported internationally. Data from the US Surveillance Epidemiology and End  
6  
7 142 Results (SEER) database for 2004-2006 indicate that 53% of eligible patients received a SLNB,<sup>18</sup> while  
8  
9 143 data from a population-based study in the northeast of France indicated that 34% of patients with a  
10  
11 144 melanoma >1mm in thickness received a SLNB.<sup>19</sup> Factors associated with having a SLNB included  
12  
13 145 patient age <50 years,<sup>17</sup> primary tumour on upper limb,<sup>17</sup> treatment in an urban setting,<sup>17,19-23</sup> and  
14  
15 146 hospital size (>50 beds)<sup>24</sup> Recent international data indicate that rates of SLNB are increasing: in the  
16  
17 147 Netherlands the SLNB rate increased from 39.0% in 2003 to 47.8% in 2014.<sup>25</sup> The authors suggested  
18  
19 148 that changes in rates of SLNB may be related to evolving views on SLNB as a staging or therapeutic  
20  
21 149 procedure, changes to the AJCC staging system, and less acceptance of the step-wise model of  
22  
23 150 disease progression.

### 22 151 *Challenges relating to implementation of clinical practice guidelines*

24  
25 152 Clinical practice guidelines synthesise and summarise complex research evidence into easily  
26  
27 153 understandable recommendations. Clinical practice guidelines were initially heralded as a means of  
28  
29 154 overcoming the knowledge gaps perceived to be behind observed variations in clinical practice.<sup>26</sup>  
30  
31 155 However, even guidelines that are based on rigorous evidence rarely penetrate medical practice as  
32  
33 156 intended.<sup>26</sup> It is now accepted that the distillation and summary of evidence into clinical practice  
34  
35 157 guidelines, although a necessary step, is not in and of itself sufficient for the translation of research  
36  
37 158 evidence into routine clinical practice.<sup>26</sup>

37 159 Successful adoption and implementation of guidelines requires an understanding of the  
38  
39 160 technical, social, political, economic, cultural, structural and psychological barriers to the use of  
40  
41 161 research evidence.<sup>27</sup> As Greenhalgh and colleagues noted in 2004, clinicians are not passive  
42  
43 162 recipients of innovations (such as guidelines).<sup>28</sup> Instead they 'seek innovations, experiment with  
44  
45 163 them, evaluate them, find (or fail to find) meaning in them, develop feelings (positive or negative)  
46  
47 164 about them, challenge them, worry about them, complain about them, "work around" them, gain  
48  
49 165 experience with them, modify them to fit particular tasks, and try to improve or re-design them—  
50  
51 166 often through dialogue with other users.' In addition, as Ferlie and colleagues noted in 2001, the  
52  
53 167 research evidence for a particular practice is often ambiguous and contested.<sup>29</sup> Consequently, the  
54  
55 168 evidence base, 'must be continually interpreted and reframed in accordance with the local context, a  
56  
57 169 process that often involves power struggles among various professional groups'.<sup>29</sup> For their  
58  
59 170 widespread acceptance, guidelines need to be perceived as authoritative, credible and professional  
60  
171 documents that help healthcare professionals improve their practice, traits closely tied to the  
172  
173 provenance of the guidelines.<sup>26</sup>

## 173 *Theoretical framework*

174 The Tailored Implementation for Chronic Disease (TICD) Checklist is a comprehensive, integrated  
175 checklist that was designed to be used as a tool to identify determinants of practice that warrant  
176 further in-depth investigation.<sup>30</sup> Although originally designed to be used in the chronic disease  
177 setting, the authors advise that it can be used more broadly.<sup>31</sup> Determinants of practice are the  
178 barriers and facilitators that might impact on implementation of an intervention. The TICD Checklist  
179 includes 57 potential determinants of practice grouped into seven domains. These seven domains  
180 are: guideline factors; individual health professional factors; patient factors; professional  
181 interactions; incentives and resources; capacity for organisational change; and social, political, and  
182 legal factors.

183 The TICD Checklist was selected for a number of reasons, specifically: (1) the TICD Checklist  
184 is a single comprehensive, integrated checklist of determinants of practice that was created through  
185 the systematic identification and synthesis of 12 previously published checklists, frameworks,  
186 taxonomies and classifications of determinants of healthcare professional practice; (2) the TICD  
187 Checklist focuses on provider behaviour rather than patient behaviour; (3) in addition to identifying  
188 determinants of practice, the TICD Checklist can also be used to inform the design of  
189 implementation strategies; and (4) the TICD Checklist includes a comprehensive range of worksheets  
190 designed to support its use.

191 The knowledge generated in this project will be used to inform future implementation  
192 strategies to support effective and widespread melanoma guideline implementation in Australia. A  
193 greater awareness of the guidelines, and the melanoma patients to whom they apply, should in turn  
194 lead to improved melanoma management and outcomes for patients, including more accurate  
195 information about prognosis and access to systemic adjuvant therapies such as immunotherapy or  
196 targeted molecular therapy for eligible patients with melanoma.

## 197 **METHODS AND ANALYSIS**

### 198 **Study design**

199 This protocol outlines the research design for a mixed-methods study informed by the TICD  
200 Checklist.<sup>30</sup> Cross-sectional questionnaires and in-depth semi-structured interviews with GPs and  
201 dermatologists, and in-depth semi-structured interviews with other healthcare professionals and  
202 stakeholders in melanoma care in Australia will be complemented by data collected through  
203 documentary analysis of material such as editorials, organisational and institutional reports, books  
204 and brochures relating to SLNB in Australia, including policy documentation (Table 2). Data collection

205 for GP questionnaires and interviews commenced in December 2018; and for other healthcare  
 206 professionals and stakeholders in May 2019. The study runs until 2023. The credibility of the study's  
 207 findings will be enhanced through the use of multiple sources of information, different methods of  
 208 data collection and the involvement of researchers with diverse areas of expertise (e.g. in clinical  
 209 practice, melanoma, implementation science, complexity science, behaviour change science and  
 210 public health). This triangulation of methods, data sources and investigator expertise will ensure that  
 211 the findings are data-rich and comprehensive.<sup>32</sup> The reporting of the study design as outlined in this  
 212 protocol is informed by the consolidated Criteria for Reporting Qualitative Research (COREQ)  
 213 checklist and the Strengthening the Reporting of Observational studies in Epidemiology (STROBE)  
 214 guidelines.<sup>33,34</sup>

### 215 **Study aim and objectives**

216 The aim of this mixed-methods study is to understand the structural, contextual and cultural factors  
 217 impacting the implementation of the recently updated national clinical practice guidelines for SLNB  
 218 in melanoma patients. The study aim will be achieved by fulfilling the objectives outlined in Table 2.

219 **Table 2 Study aim, objectives and data collection methods**

Aim	Objectives	Data collection
To understand the structural, contextual and cultural factors impacting on the implementation of the national clinical practice guidelines for SLNB for melanoma patients in Australia	Understand GPs' and dermatologists' knowledge and attitudes towards SLNB in Australia	Questionnaires and follow-up semi-structured interviews with GPs (i.e. generalist GPs and GPs working in skin cancer clinics) and dermatologists in relation to management of melanoma and role of SLNB
	Provide an account of factors that have contributed to this discourse	Semi-structured interviews with other healthcare professionals and key stakeholders in melanoma management (e.g. academics and researchers, representatives of professional colleges, healthcare training and education organisations, and consumer advocacy organisations)
	Assess the range of perspectives and opinions on SLNB among healthcare professionals and other stakeholders in Australia	
	Contextualise data collected in the interviews with other documentation	Documentary analysis of printed and electronic material

---

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23</p>	<p>Provide an account of determinants of practice that have impacted on the implementation of Australia's clinical practice guidelines for SLNB for patients with melanoma</p> <p>Generate knowledge that will help inform the future work of the CRE in Melanoma, in particular the design of implementation strategies appropriate to the determinants to improve uptake of the clinical practice guidelines for SLNB in melanoma patients in Australia</p>	<p>relating to implementation of SLNB guidelines in Australia (e.g. commentaries and editorials, books and brochures, event programs, newspapers, press releases, program proposals, summaries, organisational and institutional reports, questionnaire data, and public records)</p>
--	---	---

---

220

## 221 **Sample and setting**

### 222 *Participants*

223 Participants will include GPs, dermatologists and other healthcare professionals involved in the  
 224 diagnosis and early definitive care of melanoma patients in Australia (Box 1). It is anticipated this will  
 225 include generalist GPs, GPs working in skin cancer clinics, dermatologists and surgeons (general,  
 226 plastic and surgical oncology). Participants will also include stakeholders involved in melanoma care  
 227 in Australia, including researchers, representatives of professional colleges and organisations (e.g.  
 228 Royal Australian College of General Practitioners, Royal Australasian College of Surgeons, Australian  
 229 College of Dermatologists, Skin Cancer College Australasia), healthcare training and education  
 230 organisations (e.g. HealthCert, Australasian College of Cutaneous Oncology), and consumer advocacy  
 231 organisations (e.g. Melanoma Patients Australia).

### 232 **Box 1 Inclusion and exclusion criteria**

#### 233 Questionnaires and interviews (GPs and dermatologists)

- 234 • Must have worked as a general practitioner or dermatologist in Australia in the previous  
 235 12 months.

#### 236 Interviews (other healthcare professionals)

- 237 • Must have worked as a health professional in Australia in the previous 12 months.



238 Interviews (stakeholders)

- 239 • Current or prior experience of managing patients with melanoma in Australia; or
- 240 • Current or prior experience of working for an organisation or institution that could have
- 241 influenced healthcare practitioners', policymakers' or patients' views on SLNB in Australia.

242 Documentary analysis

- 243 • Australian online or print-based materials that could have influenced healthcare practitioners',
- 244 policymakers' or patients' views on SLNB in Australia.

245 *Sampling and recruitment: questionnaires*

246 Recruitment of dermatologists and GPs will take place at targeted conferences, training and skin  
 247 cancer-focused continuing medical education events and through professional communications, for  
 248 example by contacting organisations such as the Australasian College of Dermatologists.

249 *Sampling and recruitment: interviews*

250 Sampling will be driven by a number of purposive sampling strategies, including stratified purposive  
 251 sampling and maximum variation sampling (to gain as wide a range of perspectives as possible from  
 252 individuals with different professional backgrounds and responsibilities), key informant sampling (to  
 253 ensure important informants are included) and snowball sampling (to ensure sampling is not  
 254 restricted to key informants already known to the CRE in Melanoma members).<sup>35</sup> Sampling will be  
 255 iterative, with decisions informed by the ongoing data analysis.<sup>36</sup> Recruitment strategies will include:  
 256 (1) recruitment of healthcare professionals at relevant conferences and professional development  
 257 activities; (2) identification of key stakeholders by members of the CRE in Melanoma; and (3)  
 258 identification of additional key stakeholders by participants. The overarching recruitment strategy  
 259 will be to select for interview individuals from around Australia whose experiences and professional  
 260 roles within melanoma healthcare put them in a position to provide rich and relevant data.  
 261 Recruitment will cease once data analysis indicates thematic saturation has been reached, this being  
 262 the point at which our analysis allows us to provide a comprehensive and credible account of the  
 263 structural, contextual and cultural factors impacting on implementation of the national clinical  
 264 practice guidelines for SLNB in patients with melanoma in Australia. It is anticipated that between 50  
 265 and 65 participants will be recruited in order to ensure a variety of perspectives and experiences  
 266 from all relevant sectors in Australian melanoma care (20-25 GPs; 10-15 dermatologists; 20-25 other  
 267 healthcare professionals and stakeholders).

268 *Sampling: documentary analysis*



269 Documentary materials relevant to the development and use of the national SLNB guidelines will be  
 270 purposively sampled and included, based on their potential to provide background and contextual  
 271 information relevant to study's aims (Box 1). Relevant documentary materials (such as  
 272 commentaries and editorials, journal articles and white papers, books and brochures, event  
 273 programs, newspapers, press releases, program proposals, summaries, organisational and  
 274 institutional reports, questionnaire data, and public records) will be used to uncover meaning,  
 275 develop understanding and discover insights relevant to the study's aim.

## 276 **Data collection**

### 277 *Questionnaires*

278 Questionnaires for GPs and dermatologists have been developed following a review of literature and  
 279 consultation with melanoma clinicians and dermatologists. Data captured will include demographic  
 280 characteristics, knowledge of melanoma guidelines, clinical management of patients with  
 281 melanoma, referral patterns, attitudes to SLNB, and experiences of sharing care of patients with  
 282 melanoma with other healthcare providers (Supplementary file 2). The questionnaires can be  
 283 completed on paper or electronically. The questionnaire data will be managed using REDCap.<sup>37</sup>

### 284 *Interviews*

285 Semi-structured interview guides have been developed for healthcare professionals and  
 286 stakeholders based on a review of literature and through consultation with melanoma healthcare  
 287 professionals (Table 3). The interview guides outline the major topics that will be discussed in the  
 288 interviews and include a range of questions and prompts. Interviews will be face-to-face or by  
 289 telephone (depending on participant preference) and will be audio-recorded and professionally  
 290 transcribed. Field notes written up immediately after each interview will further inform and enrich  
 291 data analysis.

292 **Table 3 Topics and example questions from semi-structured interview guides for melanoma**  
 293 **healthcare professionals (GPs and dermatologists) and stakeholders**

Topics	Example questions
<i>Melanoma healthcare professionals</i>	
Risk factors, diagnosis and management	If you identified a suspected melanoma, how would you usually go about getting a biopsy? If you perform the biopsy yourself, how does the information in the pathology report help guide your subsequent management decisions?
SLNB	Do you have any thoughts about the role of SLNB in the management of patients with melanoma?

	What do you see as the benefits and risks of SLNB?
Shared decision-making	How comfortable would you feel about discussing melanoma management options with a patient? How do you usually tell your patient about different options for managing their melanoma?
<i>Stakeholders in melanoma care</i>	
Professional / organisational role	Can you tell me about your involvement / your organisation's involvement in SLNB for melanoma? Can you tell me about how you / your organisation regards SLNB for melanoma?
Views on current SLNB guidelines	I know you have written about SLNB, can you expand on that? There are some who hold quite extreme views on SLNB. How do you respond to these views?
Making changes in relation to SLNB	What might be the barriers to change? What do you think will happen in relation to use of SLNB in the next 5 years / 10 years?

294 SLNB: sentinel lymph node biopsy.

### 295 *Documentary analysis*

296 Documents will initially be identified through discussion with members of the Melanoma CRE, and  
297 then through targeted, systematic searches of electronic and print-based resources relating to SLNB  
298 and SLNB guidelines in Australia. Searching will be iterative and cease only when a comprehensive  
299 understanding of the background and context of SLNB in Australia has been reached.

### 300 **Data analysis**

#### 301 *Questionnaires*

302 Postcode will be classified using the Accessibility/Remoteness Index of Australia (ARIA), and Socio-  
303 Economic Indexes for Areas (SEIFA) classifications.<sup>38,39</sup> Descriptive analyses and multivariable  
304 regression models will be used to examine factors related to SLNB practices and attitudes, and  
305 familiarity with the Australian clinical practice guidelines for melanoma management, estimated  
306 using probability ratios and 95% confidence intervals (CIs). Potential predictors that will be assessed  
307 in the regression models include age, sex, type of practice, years of practice, number of invasive  
308 melanomas diagnosed in a year, location of practice and GPs' exposure to information relating to  
309 SLNB. All analyses will be conducted using SAS version 9.4 (SAS Institute Inc).

#### 310 *Interviews*

311 The interview data will be analysed using thematic analysis and this analysis will initially be inductive  
312 and data driven.<sup>40,41</sup> The analysis will be informed by, but not necessarily limited to, the TICD  
313 Checklist's seven domains: guideline factors; individual health professional factors; patient factors;  
314 professional interactions; incentives and resources; capacity for organisational change; and social,

1  
2  
3 315 political, and legal factors.<sup>30</sup> The de-identified transcripts will be read by two members of the  
4  
5 316 research team. Data will be compared within and across interviews in order to identify  
6  
7 317 commonalities, differences and patterns in the data. Transcripts will be coded by two researchers  
8  
9 318 and a list of themes and categories relevant to the study's aim generated. These themes will then be  
10  
11 319 discussed with other members of the research team and refined until agreement is reached on those  
12  
13 320 most relevant to the study's aim. A thematic map will be developed and the data recoded to these  
14  
15 321 themes. Analytic memos will be written throughout the data analysis process.

#### 16 322 *Documentary materials*

17  
18 323 The analysis process will commence by assessing the authenticity and usefulness of each document,  
19  
20 324 taking into account the document's relevance to the study's aim, the original purpose of the  
21  
22 325 document, the context in which it was produced, and the intended audience.<sup>42</sup> As with the interview  
23  
24 326 data, the documentary data will be analysed using thematic analysis.<sup>41</sup>

#### 25 327 **Indirect Patient and Public Involvement**

26  
27  
28 328 We did not directly include PPI in the design of this study, but the melanoma guidelines used in the  
29  
30 329 study were developed and updated by a committee that includes patient representatives.

31  
32 330

### 33 331 **ETHICS AND DISSEMINATION**

#### 34 332 **Ethics**

35  
36  
37  
38 333 Ethical approval for the study has been granted by the University of Sydney Human Research Ethics  
39  
40 334 Committee (HREC), project numbers 2018/713 and 2019/308. Data collection and analysis will be  
41  
42 335 conducted in accordance with the Australian National Health and Medical Research Council National  
43  
44 336 Statement.<sup>43</sup> All participants will provide informed consent prior to taking part in the study.

#### 45 337 **Data storage and protection**

46  
47  
48 338 Participant privacy and confidentiality will be maintained by removing all identifying information  
49  
50 339 from the transcripts, by assigning pseudonyms to participants, and by storing study data securely on  
51  
52 340 password-protected computers or in locked filing cabinets within university premises, to which only  
53  
54 341 named researchers from the research team will have access. Deidentified interview transcripts will  
55  
56 342 be stored separately from the file containing participant identifiers. All data will be destroyed 7 years  
57  
58 343 after completion of the study in accordance with standard ethical guidelines around storage of study  
59  
60 344 data.

1  
2  
3 345 **Dissemination of study findings**  
4

5 346 Study findings will be disseminated via peer-reviewed journal publications, generalist publications,  
6  
7 347 presentations to the public, academics, clinicians, policymakers, melanoma consumers, and at  
8  
9 348 scientific conferences.

10  
11 349 **SIGNIFICANCE AND IMPACT OF STUDY**  
12

13 350 This is the first multi-methods study to investigate the structural, contextual and cultural factors  
14  
15 351 impacting the implementation of national SLNB guidelines in Australia. The study will bring to light  
16  
17 352 the range of professional perspectives on SLNB, document the discourse surrounding SLNB in  
18  
19 353 Australia and report on how these may be affecting uptake of SLNB in patients with melanoma. The  
20  
21 354 knowledge generated by this project will be used to inform future efforts to support effective and  
22  
23 355 widespread melanoma guideline implementation in Australia and internationally. A greater  
24  
25 356 awareness of the guidelines, and the patients with melanoma to whom they apply, should in turn  
26  
27 357 lead to improved melanoma management and outcomes for patients, including more accurate  
28  
29 358 information about prognosis and access to adjuvant systemic therapies such as immunotherapy or  
30  
31 359 BRAF-directed targeted molecular therapy for eligible melanoma patients. And finally, the  
32  
33 360 knowledge generated in this study will focus attention on the role of SLNB as a diagnostic and  
34  
35 361 prognostic tool in melanoma, the role it has to play in accurate melanoma staging and cancer  
36  
37 362 registry reporting, and the role SLNB plays in the design and conduct of melanoma clinical trials both  
38  
39 363 now and in the future.

37 364 **Author statement**  
38  
39

40 365 **Acknowledgements** We thank Sam Robinson for help in preparing the ethics application.  
41

42 366 **Funding** This work was funded by the Melanoma Centre of Research Excellence grant (1135285)  
43  
44 367 from the Australian National Health and Medical Research Council. RLM received funding from an  
45  
46 368 NHMRC Translating Research into Practice (TRIP) Fellowship (1150989). AEC received a NHMRC  
47  
48 369 Career Development Fellowship (1147843) and Cancer Institute NSW Career Development  
49  
50 370 Fellowship (15/CDF/1-14).

51 371 **Competing interests** JFT has received honoraria for advisory board participation from BMS Australia,  
52  
53 372 MSD Australia, GSK and Provectus Inc, and travel support from GSK and Provectus Inc.

54  
55 373 **Contributorship statement** FR, ALS, AEC, GJM, CGW, DEG, MH, AMH, JWK, GVL, VJM, RLM, RPMS,  
56  
57 374 RAS, AJS, JFT and JB were involved in the conception of the work; AEC, GJM, RAS, JB, JWK, RLM, AJS,  
58  
59 375 RPMS, MH were involved in acquisition of the funding; ALS, FR, JB, AEC were involved in the design  
60

1  
2  
3 376 of the work; ALS drafted the manuscript; FR, ALS, AEC, GJM, CGW, DEG, MH, AMH, JWK, GVL, VJM,  
4  
5 377 RLM, RPMS, RAS, AJS, JFT and JB were involved in critically revising the manuscript.

6  
7  
8 378 **Ethics approval** University of Sydney Human Research Ethics Committee, project numbers 2018/713  
9  
10 379 and 2019/308.

11  
12 380 **Provenance and peer review** Not commissioned; externally peer reviewed.

13  
14 381 **Open Access** This is an Open Access article distributed in accordance with the Creative Commons  
15  
16 382 Attribution Non Commercial 4.0 international license (CC BY-NC 4.0), which permits others to  
17  
18 383 distribute, remix, adapt, build upon this work non-commercially, and license their derivative works  
19  
20 384 on different terms, provided the original work is properly cited and the use is non-commercial. See:  
21  
22 385 <http://creativecommons.org/licenses/by-nc/4.0/>

23  
24 386

## 25 387 REFERENCES

- 26  
27  
28 388 1. Australian Institute of Health and Welfare (AIHW). *2018 Cancer Data in Australia; Australian*  
29 389 *Cancer Incidence and Mortality (ACIM) books: melanoma of the skin*. Canberra: AIHW, 2019.  
30 390 [Accessed 19 December 2019] [https://www.aihw.gov.au/reports/cancer/cancer-data-in-](https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/)  
31 391 [australia/](https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/)  
32  
33 392  
34 393 2. Gershenwald JE, Scolyer RA, Hess KR, *et al*. Melanoma staging: evidence-based changes in the  
35 394 American Joint Committee on Cancer eighth edition cancer staging manual. *CA: A Cancer Journal*  
36 395 *for Clinicians* 2017;**67**:472–92.  
37 396  
38 397 3. Mahul AB, Edge S, Greene F, *et al*. *AJCC Cancer Staging Manual*. 8th ed. Chicago: Springer  
39 398 International Publishing, 2017.  
40 399  
41 400 4. Gershenwald JE, Scolyer RA. Melanoma Staging: American Joint Committee on Cancer (AJCC)  
42 401 8th edition and beyond. *Ann Surgical Oncol* 2018;**25**:2105–10.  
43 402  
44 403 5. Morton D, Wen D, Wong J, *et al*. Technical details of intraoperative lymphatic mapping for  
45 404 early stage melanoma. *Archives Surgery* 1992;**127**:392–9.  
46 405  
47 406 6. Mitra A, Conway C, Walker C, *et al*. Melanoma sentinel node biopsy and prediction models for  
48 407 relapse and overall survival. *British J Cancer* 2010;**103**:1229.  
49 408  
50 409 7. Morton R, Howard K, Thompson J. The cost-effectiveness of sentinel node biopsy in patients  
51 410 with intermediate thickness primary cutaneous melanoma. *Ann Surgical Oncol* 2008;**16**:929.  
52 411  
53 412 8. Faries MB, Thompson JF, Cochran AJ, *et al*. Completion dissection or observation for sentinel-  
54 413 node metastasis in melanoma. *NEJM* 2017;**376**:2211–22.  
55 414  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 415 9. Leiter U, Stadler R, Mauch C, *et al.* Complete lymph node dissection versus no dissection in  
416 patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre,  
417 randomised, phase 3 trial. *The Lancet Oncol* 2016;**17**:757–67
- 418
- 419 10. Shuchter L. Adjuvant melanoma therapy — head-spinning progress. *NEJM* 2017;**377**:1888–  
420 90.
- 421
- 422 11. Long GV, Hauschild A, Santinami M, *et al.* Adjuvant dabrafenib plus trametinib in Stage III  
423 BRAF-mutated melanoma. *NEJM* 2017;**377**:1813–23.
- 424
- 425 12. Weber J, Mandala M, Vecchio M, *et al.* Adjuvant nivolumab versus ipilimumab in resected  
426 stage III or IV melanoma. *NEJM* 2017;**377**:1824–35.
- 427
- 428 13. Eggermont A, Blank CU, Mandala M, *et al.* Adjuvant pembrolizumab versus placebo in  
429 resected Stage III melanoma. *NEJM* 2018;**378**:1789–801.
- 430
- 431 14. Amin M, Greene FL, Edge SB, *et al.* The Eighth Edition AJCC Cancer Staging Manual:  
432 continuing to build a bridge from a population-based to a more “personalized” approach to  
433 cancer staging. *CA: A Cancer Journal for Clinicians* 2017;**67**:93–9.
- 434
- 435 15. Gyorki D, Barbour A, Mar V, *et al.* Cancer Council Australia Melanoma Guidelines Working  
436 Party. When is a sentinel node biopsy indicated? 2019.  
437 [http://wiki.cancer.org.au/australia/Clinical\\_question:When\\_is\\_a\\_sentinel\\_node\\_biopsy\\_indicate](http://wiki.cancer.org.au/australia/Clinical_question:When_is_a_sentinel_node_biopsy_indicate)  
438 [d%3F](http://wiki.cancer.org.au/australia/Clinical_question:When_is_a_sentinel_node_biopsy_indicate). [Accessed 19 December 2019].
- 439
- 440 16. Smithers MB, Hughes MB, Beesley VL, *et al.* Prospective study of patterns of surgical  
441 management in adults with primary cutaneous melanoma at high risk of spread, in Queensland,  
442 Australia. *J Surgical Oncol* 2015;**112**:359–65.
- 443
- 444 17. Varey AH, Madronio CM, Cust AE, *et al.* Poor adherence to National Clinical Management  
445 Guidelines: a population-based, cross-sectional study of the surgical management of melanoma  
446 in New South Wales, Australia. *Ann Surgical Oncol* 2017;**24**:2080–8.
- 447
- 448 18. Silva E. Adjunct primer for the use of national comprehensive cancer network guidelines for  
449 the surgical management of cutaneous malignant melanoma patients. *World J Surgical Oncol*  
450 2012;**10**:54.
- 451
- 452 19. Grange F, Vitry F, Granel-Brocard F, *et al.* Variations in management of Stage I to Stage III  
453 cutaneous melanoma: a population-based study of clinical practices in France. *Arch Dermatol*  
454 2008;**144**:629–36.
- 455
- 456 20. Shah DR, Yang AD, Maverakis E, *et al.* Assessing rural–urban disparities in the use of sentinel  
457 lymph node biopsy for melanoma. *J Surg Res* 2013;**184**:1157–60.
- 458
- 459 21. Sant M, Minicozzi P, Allemani C, *et al.* Regional inequalities in cancer care persist in Italy and  
460 can influence survival. *Cancer Epidemiology* 2012;**36**:541–7.
- 461
- 462 22. Hong NJ, Cheng SY, Baxter NN, *et al.* Melanoma patterns of care in Ontario: a call for a




- 1  
2  
3 463 strategic alignment of multidisciplinary care. *J Surgical Oncol* 2018;117:597–617.  
4 464  
5 465 23. Rivard J, Kostaras X, Shea-Budgell M, *et al.* A population-based assessment of melanoma:  
6 466 does treatment in a regional cancer center make a difference? *J Surg Oncol* 2015;112:173–8.  
7 467  
8 468 24. Garreau JR, Nelson J, Cook D, *et al.* Geographic variation in sentinel node adaptation by  
9 469 practicing surgeons in Oregon. *Am J Surg* 2005;189:616–20.  
10 470  
11 471 25. Sharouni M-A, Witkamp AJ, Sigurdsson V, *et al.* Trends in sentinel lymph node biopsy  
12 472 enactment for cutaneous melanoma. *Ann Surgical Oncol* 2019;26:1494–502.  
13 473  
14 474 26. Dopson S, Locock L, Gabbay J, *et al.* Evidence-based medicine and the implementation gap.  
15 475 *Health*: 2003;7:311–30.  
16 476  
17 477 27. Bosk CL, Dixon-Woods M, Goeschel CA, *et al.* Reality check for checklists. *Lancet*  
18 478 2009;374:444–5.  
19 479  
20 480 28. Greenhalgh T, Robert G, MacFarlane F, *et al.* Diffusion of Innovations in Service  
21 481 Organizations: systematic review and recommendations. *Milbank Quarterly* 2004;82:581–629.  
22 482  
23 483 29. Ferlie E, Gabbay J, Fitzgerald L, *et al.* Evidence-based medicine and organisational change: an  
24 484 overview of some recent qualitative research. In: *Organisational behaviour and organisational*  
25 485 *studies in health care: Reflections on the future*. Eds: Ashburner, L. Basingstoke: Palgrave  
26 486 Macmillan, 2001; pp18–42.  
27 487  
28 488 30. Flottorp SA, Oxman AD, Krause J, *et al.* A checklist for identifying determinants of practice: a  
29 489 systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable  
30 490 improvements in healthcare professional practice. *Implementation Science* 2013;8:35.  
31 491  
32 492 31. Wensing M, Oxman A, Baker R, *et al.* Tailored implementation for chronic diseases (TICD): a  
33 493 project protocol. *Implementation Science* 2011;6:103.  
34 494  
35 495 32. Rapport F, Hogden A, Faris M, *et al.* *Qualitative research in healthcare: modern methods,*  
36 496 *clear translation. A white paper*. Sydney: Macquarie University, 2018.  
37 497  
38 498 33. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ):  
39 499 a 32-item checklist for interviews and focus groups. *Int J Qual Health Care* 2007;19:349–57.  
40 500  
41 501 34. von Elm E, Altman DG, Egger M, *et al.* The strengthening the reporting of observational  
42 502 studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Int J*  
43 503 *Surg* 2014;12:1495–9.  
44 504  
45 505 35. Miles M, Huberman M. *Qualitative data analysis: an expanded sourcebook*. Thousand Oaks:  
46 506 SAGE Publishing, 1994.  
47 507  
48 508 36. Charmaz K. *Constructing grounded theory: a practical guide through qualitative analysis*.  
49 509 Thousand Oaks: SAGE Publications, 2006.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60 509 37. Harris PA, Taylor R, Thielke R, *et al.* Research electronic data capture (REDCap)—A metadata-

- 1  
2  
3 510 driven methodology and workflow process for providing translational research informatics  
4 511 support. *J Biomed Inform* 2009;**42**:377–81.  
5 512  
6  
7 513 38. Australian Bureau of Statistics (ABS). *Socio-Economic Indexes for Areas (SEIFA)*. ABS 2018.  
8 514 <http://www.abs.gov.au/websitedbs/censushome.nsf/home/seifa>.  
9 515  
10 516 39. Australian Bureau of Statistics (ABS). *The Australian Statistical Geography Standard (ASGS)*  
11 517 *remoteness structure*. ABS 2018.  
12 518 <http://www.abs.gov.au/websitedbs/d3310114.nsf/home/remoteness+structure13>.  
13 519  
14 520 40. Clarke V, Braun V. Reflecting on thematic analysis. *Qual Res Sport Exercise Health* 2019;**11**:1–  
15 521 2.  
16 522  
17 523 41. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychology* 2006;**3**:77–  
18 524 101.  
19 525  
20 526 42. Bowen G. Document analysis as a qualitative research method. *Qualitative Res J* 2009;**9**:27–  
21 527 40.  
22 528  
23 529 43. The National Health and Medical Research Council, the Australian Research Council and  
24 530 Universities Australia. *National Statement on Ethical Conduct in Human Research 2007 (Updated*  
25 531 *2018)*. Canberra: Commonwealth of Australia, 2018.



# Preliminary mapping exercise: melanoma care continuum / CRE in Melanoma activities




CRUENT / PROPOSED  
CORE 2 CRE ACTIVITIES

bmjopen-2019-02636 on 27 February 2020. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

# Preliminary mapping exercise: melanoma care continuum / CRE in Melanoma activities


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46



CRUEENT / PROPOSED  
CORE 2 CRE ACTIVITIES

bmjopen-2019-02636 on 27 February 2020. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

# Preliminary mapping exercise: melanoma care continuum / CRE in Melanoma activities




CRUJENT / PROPOSED  
CORE 3 CRE ACTIVITIES

bmjopen-2019-02636 on 27 February 2020. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

# Preliminary mapping exercise: melanoma care continuum / CRE in Melanoma activities



bmjopen-2019-02636 on 27 February 2020. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

# Preliminary mapping exercise: melanoma care continuum / CRE in Melanoma activities



bmjopen-2019-02636 on 27 February 2020 downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46



THE UNIVERSITY OF  
**SYDNEY**



Cancer Epidemiology and Prevention Research  
School of The University of Sydney  
Faculty of Medicine and Health

## Melanoma management survey for GPs

1. What best describes the type of practice you work in?

- Independent GP practice
- Medical centre practice
- Skin cancer clinic
- Other (please specify): \_\_\_\_\_

2. What is the postcode or suburb/town of your practice? \_\_\_\_\_

3. What is your gender?

- Female
- Male

4. What is your age?

- < 30 years
- 30-39 years
- 40-49 years
- 50-59 years
- 60-69 years
- 70+ years

5. How many patients would you usually see with invasive melanoma in one year (i.e. not including melanoma in situ/lentigo maligna)?

- None
- 1 patient per year
- 2-5 patients per year
- 6-10 patients per year
- 11-30 patients per year
- >30 patients per year

6. How many years have you been practising as a GP?

- <5 years
- 6-10 years
- 11-20 years
- 21-30 years
- 31-40 years
- >40 years

7. On a scale of 1 to 5, how familiar are you with the national clinical practice guidelines for melanoma management? **(tick one only)**

- 1 - Very unfamiliar
- 2 - Somewhat unfamiliar
- 3 - A little familiar
- 4 - Quite familiar
- 5 - Very familiar

Melanoma management study, GP survey

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1  
2  
3 8. Have you accessed the recent update of the national clinical practice guidelines for melanoma on the  
4 Cancer Council Australia website/Wiki?

- 5  No  
6  Yes

7  
8 9. Have you read any articles (e.g. in journals, magazines, newsletters) or listened to talks about sentinel  
9 lymph node biopsy (SLNB) for melanoma in the last 3 years?

- 10  No → go to question 11  
11  Yes → **tick all that apply**  
12      Australian Family Physician  
13      Australian Journal of General Practice (AJGP)  
14      Medical Journal of Australia (MJA)  
15      Other peer-reviewed journal, please specify: \_\_\_\_\_  
16      Newspaper  
17      Conference lecture  
18      Workshop or seminar  
19      Other, please specify \_\_\_\_\_  
20  
21  
22

23  
24 10. Do you think these articles or presentations have influenced your attitude to sentinel lymph node  
25 biopsy for melanoma?

- 26  No  
27  Yes → How have they influenced you? \_\_\_\_\_  
28  
29

30  
31  
32 11. Do you think that sentinel lymph node biopsy has an important role in the management of melanoma  
33 patients?

- 34  No → Why not? \_\_\_\_\_  
35  Yes  
36  Unsure  
37  
38  
39

40  
41 12. Would you usually discuss and recommend sentinel lymph node biopsy to a patient with a newly  
42 diagnosed melanoma, if eligible for sentinel lymph node biopsy?

- 43  No → go to question 21  
44  Yes → go to question 13  
45  
46  
47

48 13. Why do you believe that sentinel lymph node biopsy may be of value? (**tick all that apply**)

- 49  More accurate staging and prognostic information  
50  Likely survival benefit  
51  Influence of the results on patient management  
52  To assess suitability for adjuvant systemic therapies for melanoma patients who are found to be  
53 sentinel lymph node positive  
54  To select patients for completion lymphadenectomy  
55  Other (please specify): \_\_\_\_\_  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

14. At what Breslow thickness or other criteria would you tell a patient that sentinel lymph node biopsy would be appropriate? **(tick all that apply)**

- <0.80 mm
- <0.80 mm and other high-risk pathological feature/s
- 0.80 - 1.00 mm
- 0.80 - 1.00 mm and other high-risk pathological feature/s
- 1.01 - 2.00 mm
- 2.01 - 4.00 mm
- >4.00 mm
- Other criteria, please specify \_\_\_\_\_

15. Would any of these factors influence your decision to discuss or recommend sentinel lymph node biopsy to patients? **(tick all that apply)**

- Breslow thickness
- Presence of ulceration
- Mitotic rate of the melanoma
- Lymphovascular invasion in the melanoma
- Body site of the melanoma
- Presence of palpable regional lymph nodes
- Histological subtype, e.g. superficial spreading, nodular, lentigo maligna melanoma
- Age of the patient
- Comorbidities of the patient
- The morbidity of the sentinel lymph node biopsy procedure
- The morbidity of completion lymphadenectomy
- The likelihood that the results will influence patient management
- Access to services for sentinel lymph node mapping and biopsy
- Distance to services for sentinel lymph node mapping and biopsy
- Costs to the patient
- Patient level of anxiety
- Patient preference
- Other, please specify \_\_\_\_\_

16. For patients for whom sentinel lymph node biopsy would be suitable, who would you usually refer the patient to for definitive management? **(tick one only)**

- A local general surgeon
- Any surgical oncologist
- A melanoma-trained surgical oncologist
- Any plastic surgeon
- A melanoma trained plastic surgeon
- A Skin Cancer Clinic colleague
- Any Dermatologist
- A melanoma specialist dermatologist
- A specialist melanoma service where there is a multidisciplinary team
- Other, please specify: \_\_\_\_\_



1  
2  
3 17. Would you expect the clinician to whom you refer the patient, to recommend a sentinel lymph node  
4 biopsy if they were eligible? **(tick one only)**

- 5  No, never  
6  Occasionally  
7  Most of the time  
8  Yes, always  
9

10  
11 18. After a negative sentinel lymph node biopsy, are you wanting to be involved in ongoing patient follow-  
12 up? **(tick one only)**

- 13  No  
14  Yes, with follow-up managed mainly by myself  
15  Yes, with follow-up managed mainly by the specialist  
16  Yes, with follow-up managed in a shared care arrangement between the specialist and myself  
17

18 19. After a positive sentinel lymph node biopsy, are you wanting to be involved in ongoing patient follow-  
19 up? **(tick one only)**

- 20  No  
21  Yes, with follow-up managed mainly by myself  
22  Yes, with follow-up managed mainly by the specialist  
23  Yes, with follow-up managed in a shared care arrangement between the specialist and myself  
24  
25

26 20. Are there any tests or scans that you would arrange for patients eligible for sentinel lymph node  
27 biopsy? **(tick all that apply)**

- 28  No other tests or scans  
29  Ultrasound examination of regional nodes  
30  Chest X ray  
31  CT Chest/abdomen/pelvis  
32  Whole body PET-CT  
33  CT or MRI scan of brain  
34  Other, please specify: \_\_\_\_\_  
35  
36

37 → Please go to question 22  
38  
39

40 *[Note Question 21 is only for those who selected 'No' at Question 12]*  
41  
42

43 21. Why would you not usually recommend sentinel lymph node biopsy? **(tick all that apply)**

- 44  Don't know much about it  
45  Difficulty in accessing facilities for sentinel lymph node biopsy  
46  No confirmed survival benefit  
47  Does not add sufficient additional prognostic information  
48  Does not impact subsequent management  
49  The morbidity of the procedure  
50  The morbidity of completion lymphadenectomy if the sentinel node is positive  
51  Costs to the patient  
52  Other, please specify: \_\_\_\_\_  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 22. Would you be willing to be contacted by the research team for a 20 minute confidential interview to  
3 discuss risk factors, diagnosis and management of patients with melanoma by general practitioners?  
4

5 We would reimburse your time with a \$100 Coles/Myer gift voucher.

- 6  Yes → Please enter your contact details below and ask the research team for a Participant  
7 Information Sheet and Consent form for the interview study. Your contact details will be stored  
8 separately to your survey and interview data.  
9  No → continue to next page  
10

11  
12  
13 Your Name: \_\_\_\_\_  
14

15 Best contact phone number: \_\_\_\_\_  
16

17 Email address: \_\_\_\_\_  
18

19 Best time and/or day of the week: \_\_\_\_\_  
20  
21

22  
23  
24 *Continue to next page*  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2 23. Would you like to receive a summary of the results of this study after it has been completed, in about 1  
3 year's time?

4  Yes → please enter your email address: \_\_\_\_\_.

5 Your email address will not be linked to your survey responses and will be stored separately.

6  
7  No

8  
9  
10  
11 24. Please enter your email address if you would like to go into a lucky draw to win one of three iPads. The  
12 draw will take place when recruitment to the study is complete.

13 Email address: \_\_\_\_\_

14 Your email address will not be linked to your survey responses and will be stored separately.

15  
16  
17  
18 *You have completed the questionnaire! Thank you very much for your time.*

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## Melanoma management survey for Dermatologists

1. What best describes the type of practice you work in?

- Independent specialist practice
- Dermatology group specialist practice
- Melanoma Unit
- Other (please specify): \_\_\_\_\_

2. What is the postcode or suburb/town of your practice? \_\_\_\_\_

3. What is your gender?

- Female
- Male

4. What is your age?

- < 30 years
- 30-39 years
- 40-49 years
- 50-59 years
- 60-69 years
- 70+ years

5. How many patients would you usually see with invasive melanoma in one year (i.e. not including melanoma in situ/lentigo maligna)?

- None
- 1 patient per year
- 2-4 patients per year
- 6-10 patients per year
- 11-30 patients per year
- >30 patients per year

1 6. How many years have you been practising as a Dermatologist?  
2

- 3  <5 years  
4  6-10 years  
5  11-20 years  
6  21-30 years  
7  31-40 years  
8  >40 years  
9

10 7. On a scale of 1 to 5, how familiar are you with the Australian “Clinical Practice Guidelines for the  
11 Diagnosis and Management of Melanoma”?  
12

13 **(tick ONE only)**

- 14  1 - Very unfamiliar  
15  2 - Somewhat unfamiliar  
16  3 - A little familiar  
17  4 - Quite familiar  
18  5 - Very familiar  
19

20 8. Have you accessed the recent update of the Australian “Clinical Practice Guidelines for the Diagnosis and  
21 Management of Melanoma” on the Cancer Council Australia website/Wiki?  
22

- 23  No  
24  Yes  
25

26 9. Have you read any articles (e.g. in journals, magazines, newsletters) or listened to talks about sentinel  
27 lymph node biopsy (SLNB) for melanoma in the last 3 years?  
28

- 29  No → go to question 11  
30  Yes → **tick ALL that apply**  
31  Australasian Journal of Dermatology  
32  Medical Journal of Australia (MJA)  
33  Journal of the American Academy of Dermatology (JAAD)  
34  British Journal of Dermatology (BJD)  
35  New England Journal of Medicine (NEJM)  
36  Other peer-reviewed journal, please specify: \_\_\_\_\_  
37  Australian Conference  
38  International Conference  
39  Other, please specify \_\_\_\_\_  
40

41 10. Do you think these articles or presentations have influenced your attitude to sentinel lymph node  
42 biopsy for melanoma?  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  No
- 2
- 3  Yes – more likely to recommend SLNB
- 4
- 5  Yes – less likely to recommend SLNB
- 6

7 How have they influenced you? \_\_\_\_\_

8

9

10 11. Do you think that sentinel lymph node biopsy has an important role in the management of melanoma

11 patients?

12

- 13  No → Why not? \_\_\_\_\_
- 14
- 15  Yes
- 16
- 17  Unsure → Why not? \_\_\_\_\_
- 18
- 19

20 12. Would you usually discuss and recommend sentinel lymph node biopsy to a patient with a newly

21 diagnosed melanoma, if eligible for sentinel lymph node biopsy?

22

23

- 24  No → go to question 13
- 25
- 26  Yes → go to question 14
- 27
- 28

29 **[Note Question 13 is only for those who selected 'NO' at Question 12]**

30

31 13. Why would you not usually recommend sentinel lymph node biopsy?

32

33 **(tick ALL that apply)**

34

- 35  Don't know much about it
- 36
- 37  No added value of sentinel lymph node biopsy
- 38
- 39  Difficulty in accessing facilities for sentinel lymph node biopsy
- 40
- 41  No confirmed overall survival benefit
- 42
- 43  Does not add additional prognostic information beyond what is provided by Breslow thickness
- 44
- 45  Does not impact subsequent management
- 46
- 47  The morbidity of the procedure
- 48
- 49  The morbidity of completion lymphadenectomy if the sentinel node is positive
- 50
- 51  Costs to the patient
- 52
- 53  Other, please specify: \_\_\_\_\_

54 **Continue to Question 23 [page 6]**

55

56

57

58

59

60

**[Note Question 14 is only for those who selected 'YES' at Question 12]**

14. Why do you believe that sentinel lymph node biopsy may be of value for eligible patients?

**(tick ALL that apply)**

- More accurate staging
- To provide prognostic information
- Likely survival benefit
- Results may influence follow-up plan
- To assess suitability for adjuvant systemic therapies if found to be sentinel lymph node positive
- To select patients for completion lymphadenectomy
- Improved regional control
- Other (please specify): \_\_\_\_\_

15. At what Breslow thickness would you advise a patient that sentinel lymph node biopsy would be appropriate and refer them to a surgeon for management?

**(tick ALL that apply)**

- <0.80 mm
- <0.80 mm with high-risk pathological feature/s
- 0.80 - 1.00 mm
- 0.80 - 1.00 mm with high-risk pathological feature/s
- 1.01 - 2.00 mm
- 2.01 - 4.00 mm
- >4.00 mm
- None of the above (I would not refer for SLNB)

1 16. Would any of these factors influence your decision to discuss or recommend sentinel lymph node  
2 biopsy to patients?  
3

4 **(tick ALL that apply)**

- 5  Breslow thickness
- 6  Presence of ulceration
- 7  Mitotic rate of the melanoma
- 8  Lymphovascular invasion in the melanoma
- 9  Body site of the melanoma
- 10  Wide excision already performed
- 11  Type of wound closure following diagnostic biopsy
- 12  Presence of palpable regional lymph nodes
- 13  Histological subtype, e.g. desmoplastic, nodular, lentigo maligna melanoma
- 14  Age of the patient
- 15  Comorbidities of the patient
- 16  Possible morbidity of the sentinel lymph node biopsy procedure
- 17  Possible morbidity of completion lymphadenectomy
- 18  The likelihood that the results will influence patient management
- 19  Access to services for sentinel lymph node mapping and biopsy
- 20  Distance to services for sentinel lymph node mapping and biopsy
- 21  Costs to the patient
- 22  Patient level of anxiety
- 23  Patient preference
- 24  Other, please specify \_\_\_\_\_

25 17. For patients for whom sentinel lymph node biopsy would be suitable, who would you usually refer the  
26 patient to for definitive management?  
27

28 **(tick ONE only)**

- 29  A local general surgeon
- 30  Any surgical oncologist
- 31  A melanoma-trained surgical oncologist
- 32  Any plastic surgeon
- 33  A melanoma-trained plastic surgeon
- 34  A melanoma specialist dermatologist
- 35  A specialist melanoma service where there is a multidisciplinary team
- 36  None of the above (I would not refer for SLNB)



- 1            Other, please specify: \_\_\_\_\_

2  
3 18. Would you expect the clinician to whom you refer the patient to recommend a sentinel lymph node  
4 biopsy if they were eligible?

5  
6 **(tick ONE only)**

- 7            No, never  
8  
9            Occasionally  
10  
11            Most of the time if appropriate for the patient's situation  
12  
13            Yes, always  
14  
15            I would not refer to a surgeon who routinely recommends SLNB  
16

17 19. After a negative sentinel lymph node biopsy for melanoma, do you wish to be involved in ongoing  
18 patient follow-up for recurrence?

19  
20 **(tick ONE only)**

- 21            No  
22  
23            Yes, with follow-up managed mainly by myself  
24  
25            Yes, with follow-up managed mainly by the surgeon  
26  
27            Yes, with follow-up managed in a shared care arrangement between the surgeon and myself  
28  
29

30 20. After a positive sentinel lymph node biopsy for melanoma, do you wish to be involved in ongoing  
31 patient follow-up for recurrence?

32  
33 **(tick ONE only)**

- 34            No  
35  
36            Yes, with follow-up managed mainly by myself  
37  
38            Yes, with follow-up managed mainly by the surgeon or medical oncologist  
39  
40            Yes, with follow-up managed in a shared care arrangement between the surgeon or medical  
41 oncologist and myself  
42

43 21. Are there any tests or scans that you would arrange for patients eligible for sentinel lymph node biopsy  
44 at the time of diagnosis?

45  
46 **(tick ALL that apply)**

- 47            No other tests or scans  
48  
49            Ultrasound examination of regional nodes  
50  
51            Chest X ray  
52  
53            CT chest/abdomen/pelvis  
54  
55            Whole body PET-CT  
56  
57            CT or MRI scan of brain  
58  
59            Other, please specify: \_\_\_\_\_  
60

1 22. Are there any tests or scans that you would arrange for follow-up of patients diagnosed with melanoma  
2 >1 mm?  
3

4 **(tick ALL that apply)**

- 5  No other tests or scans  
6  
7  Ultrasound examination of regional nodes  
8  
9  Chest X ray  
10  
11  CT chest/abdomen/pelvis  
12  
13  Whole body PET-CT  
14  
15  CT or MRI scan of brain  
16  
17  Other, please specify: \_\_\_\_\_  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

*Continue to next page*

For peer review only

ID number: \_\_\_\_\_

1 23. Would you like to receive a summary of the results of this study after it has been completed, in about 1  
2 years' time?  
3

4  Yes → please enter your email address: \_\_\_\_\_  
5

6 *Your email address will not be linked to your survey responses and will be stored separately.*  
7

8  No  
9

10 24. Would like to go into a lucky draw to win one of three iPads? The draw will take place when recruitment  
11 to the study is complete.  
12

13  Yes → please enter your email address: \_\_\_\_\_  
14

15 *Your email address will not be linked to your survey responses and will be stored separately.*  
16

17  No  
18

19 25. Would you be willing to be contacted by the research team for a 20-minute confidential interview to  
20 discuss risk factors, diagnosis and management of patients with melanoma by dermatologists? We would  
21 reimburse your time with a \$100 Coles/Myer gift voucher.  
22

23  Yes → Please enter your contact details below and ask the research team for a Participant  
24 Information Sheet and Consent form for the interview study. Your contact details will be stored  
25 separately to your survey and interview data.  
26

27  No  
28

29  
30 Your Name: \_\_\_\_\_  
31

32  
33  
34 Best contact phone number: \_\_\_\_\_  
35

36  
37  
38 Email address: \_\_\_\_\_  
39

40  
41  
42 Best time and/or day of the week: \_\_\_\_\_  
43

44  
45 ***You have completed the questionnaire! Thank you very much for your time.***  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60